

ACTEMRA SQ

Products Affected

- Actemra ACTPen
- Actemra subcutaneous

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD. |
| Required Medical Information | Diagnosis, concurrent medications, previous drugs tried. |
| Age Restrictions | Interstitial lung disease-18 years and older (initial and continuation) |
| Prescriber Restrictions | RA/GCA/PJIA/SJIA - Prescribed by or in consultation with a rheumatologist (initial therapy). Lung disease-presc/consult-pulmonologist or rheum (initial and cont) |
| Coverage Duration | Approve through 12/31/23 |
| Other Criteria | RA initial - approve if the patient meets one of the following (A or B): A) patient has tried TWO of the following drugs in the past: Enbrel, Humira, Rinvoq or Xeljanz/XR (Note: if the patient does not meet this requirement, previous trial(s) with the following drugs will be counted towards meeting the try TWO requirement: Cimzia, infliximab, golimumab SC/IV, Orencia), OR B) patient has heart failure or a previously treated lymphoproliferative disorder. PJIA, initial-approve if the patient meets one of the following (A or B): A) patient has tried TWO of the following drugs in the past: Enbrel, Xeljanz or Humira. (Note: if the patient does not meet this requirement, a previous trial with the drug infliximab or Orencia will be counted towards meeting the try TWO requirement), OR B) patient has heart failure or a previously treated lymphoproliferative disorder. Cont tx, RA/PJIA - approve if the pt had a response as determined by the prescriber. Interstitial lung disease associated with systemic sclerosis initial-approve if the patient has elevated acute phase reactants AND the diagnosis is confirmed by high-resolution computed tomography. Interstitial lung disease assoc with systemic sclerosis, Cont tx-approve if the patient had adequate efficacy. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ACYCLOVIR (TOPICAL)

Products Affected

- acyclovir topical ointment

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ADEMPAS

Products Affected

- Adempas

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | PAH and CTEPH- must be prescribed by or in consultation with a cardiologist or a pulmonologist. |
| Coverage Duration | 1 year |
| Other Criteria | For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ALECENSA

Products Affected

- Alecensa

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Non-small cell lung cancer-approve if the patient has metastatic disease and anaplastic lymphoma kinase (ALK)-positive non-small cell lung disease. Anaplastic large cell lymphoma-approve if the patient has ALK-positive disease. Erdheim-Chester disease-approve if the patient has ALK rearrangement/fusion-positive disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Anaplastic large cell lymphoma, Erdheim Chester disease |
| Part B Prerequisite | No |

ALPHA 1 PROTEINASE INHIBITORS

Products Affected

- Prolastin-C intravenous recon soln

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Alpha1-Antitrypsin Deficiency with Emphysema (or Chronic Obstructive Pulmonary Disease)-approve if the patient has a baseline (pretreatment) AAT serum concentration of less than 80 mg/dL or 11 micromol/L |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ALUNBRIG

Products Affected

- Alunbrig oral tablet 180 mg, 30 mg, 90 mg
- Alunbrig oral tablets,dose pack

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | ALK status |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Erdheim-Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory myofibroblastic tumor (IMT)-approve if the patient has IMT with ALK translocation. Metastatic NSCLC, must be ALK-positive, as detected by an approved test. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Erdheim-Chester disease, Inflammatory myofibroblastic tumor (IMT) |
| Part B Prerequisite | No |

ANABOLIC STEROIDS

Products Affected

- oxandrolone

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients w/Turner's Syndrome or Ullrich-Turner Syndrome (oxandrolone only), management of protein catabolism w/burns or burn injury (oxandrolone only), AIDS wasting and cachexia |
| Part B Prerequisite | No |

ANTIBIOTICS (IV)

Products Affected

- amikacin injection solution 500 mg/2 mL
- ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg
- ampicillin-sulbactam injection
- azithromycin intravenous
- aztreonam
- Bicillin L-A
- cefoxitin
- ceftazidime
- cefuroxime sodium injection recon soln 750 mg
- cefuroxime sodium intravenous recon soln 1.5 gram
- ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 mL
- clindamycin in 5 % dextrose
- clindamycin phosphate injection
- clindamycin phosphate intravenous
- colistin (colistimethate Na)
- Doxy-100
- ertapenem
- gentamicin in NaCl (iso-osm) intravenous piggyback 100 mg/100 mL, 60 mg/50 mL, 80 mg/100 mL, 80 mg/50 mL
- gentamicin injection solution 40 mg/mL
- imipenem-cilastatin
- levofloxacin in D5W intravenous piggyback 500 mg/100 mL, 750 mg/150 mL
- levofloxacin intravenous
- linezolid in dextrose 5%
- meropenem intravenous recon soln 1 gram, 500 mg
- metronidazole in NaCl (iso-os)
- moxifloxacin-sod.chloride(iso)
- nafcillin injection
- oxacillin in dextrose(iso-osm)
- oxacillin injection
- penicillin G potassium injection recon soln 20 million unit
- penicillin G procaine intramuscular syringe 1.2 million unit/2 mL
- penicillin G sodium
- streptomycin
- Tazicef injection
- Teflaro
- tigecycline
- tobramycin sulfate injection solution
- vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg

| PA Criteria | Criteria Details |
|------------------------------|------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------------|
| Coverage Duration | 3 months |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ANTIFUNGALS (IV)

Products Affected

- fluconazole in NaCl (iso-osm) intravenous piggyback 200 mg/100 mL, 400 mg/200 mL
- voriconazole

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 months |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ARCALYST

Products Affected

- Arcalyst

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Concurrent biologic therapy |
| Required Medical Information | N/A |
| Age Restrictions | Initial tx CAPS/Pericarditis-Greater than or equal to 12 years of age. |
| Prescriber Restrictions | Initial tx CAPS-prescribed by, or in consultation with, a rheumatologist, geneticist, allergist/immunologist, or dermatologist. DIRA initial-rheum, geneticist, dermatologist, or a physician specializing in the treatment of autoinflammatory disorders. Pericarditis-cardiologist or rheum |
| Coverage Duration | CAPS-3 mos initial, 1 yr cont. DIRA-6 mos initial, 1 yr cont. Pericard-3 mos initial, 1 yr cont |
| Other Criteria | CAPS renewal - approve if the patient has had a response as determined by the prescriber. DIRA initial-approve if the patient weighs at least 10 kg, genetic test confirms a mutation in the IL1RN gene and the patient has demonstrated a clinical benefit with anakinra subcutaneous injection. DIRA cont-approve if the patient has responded to therapy. Pericarditis initial-approve if the patient has recurrent pericarditis AND for the current episode, the patient is receiving standard treatment or standard treatment is contraindicated. Continuation-approve if the patient has had a clinical response. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ARIKAYCE

Products Affected

- Arikayce

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous medication history |
| Age Restrictions | MAC-18 years and older (initial therapy) |
| Prescriber Restrictions | MAC initial-Prescribed by a pulmonologist, infectious disease physician or a physician who specializes in the treatment of MAC lung infections. Cystic fibrosis-prescribed by or in consultation with a pulmonologist or physician who specializes in the treatment of cystic fibrosis. |
| Coverage Duration | Initial-1 year, Cont, negative culture approve up to 1yr total, positive culture-1 year |
| Other Criteria | MAC Lung disease, initial-approve if the patient has a positive sputum culture for mycobacterium avium complex and the culture was collected within the past 3 months and was collected after the patient has completed a background multidrug regimen, the Mycobacterium avium complex isolate is susceptible to amikacin with a minimum inhibitor concentration (MIC) of less than or equal to 64 microgram/mL AND Arikayce will be used in conjunction to a background multidrug regimen. Note-a multidrug regimen typically includes a macrolide (azithromycin or clarithromycin), ethambutol and a rifamycin (rifampin or rifabutin). MAC Lung Disease, continuation-approve if Arikayce will be used in conjunction with a background multidrug regimen AND i. Patient meets ONE of the following criteria (a or b):a)patient has not achieved negative sputum cultures for Mycobacterium avium complex OR b) patient has achieved negative sputum cultures for Mycobacterium avium complex for less than 12 months. Cystic fibrosis-patient has pseudomonas aeruginosa in culture of the airway. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Cystic fibrosis pseudomonas aeruginosa infection |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

AYVAKIT

Products Affected

- Ayvakit

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | GIST-approve if the tumor is positive for platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation or if the patient has tried two of the following: Gleevec (imatinib), Sutent (sunitinib), Sprycel (dasatinib), Stivarga (regorafenib) or Qinlock (ripretinib). Myeloid/Lymphoid Neoplasms with eosinophilia-approve if the tumor is positive for PDGFRA D842V mutation. Systemic mastocytosis-Approve if the patient has a platelet count greater than or equal to 50,000/mcL and patient has one of the following subtypes of advanced systemic mastocytosis-aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Myeloid/Lymphoid neoplasms with Eosinophilia |
| Part B Prerequisite | No |

BALVERSA

Products Affected

- Balversa

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous therapies, test results |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Urothelial Carcinoma, locally advanced or metastatic-approve if the patient has susceptible fibroblast growth factor receptor 3 or fibroblast growth factor receptor 2 genetic alterations AND the patient has progressed during or following prior platinum-containing chemotherapy or checkpoint inhibitor therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BENLYSTA

Products Affected

- Benlysta subcutaneous

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent Use with Other Biologics or Lupkynis |
| Required Medical Information | Diagnosis, medications that will be used in combination, autoantibody status |
| Age Restrictions | 18 years and older (initial). |
| Prescriber Restrictions | SLE-Prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist or dermatologist (initial and continuation). Lupus Nephritis-nephrologist or rheum. (Initial/cont) |
| Coverage Duration | SLE-Initial-4 months, cont-1 year. Lupus Nephritis-6 mo initial, 1 year cont |
| Other Criteria | Lupus Nephritis Initial-approve if the patient has autoantibody-positive SLE, defined as positive for antinuclear antibodies [ANA] and/or anti-double-stranded DNA antibody [anti-dsDNA]. Cont-approve if the patient has responded to the requested medication. SLE-Initial-The patient has autoantibody-positive SLE, defined as positive for antinuclear antibodies [ANA] and/or anti-double-stranded DNA antibody [anti-dsDNA] AND Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity, as determined by the prescribing physician. Continuation-Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity, as determined by the prescribing physician AND The patient has responded to Benlysta as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

BESREMI

Products Affected

- Besremi

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Concomitant use with other interferon products |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BETASERON/EXTAVIA

Products Affected

- Betaseron subcutaneous kit

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agent used for multiple sclerosis |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or after consultation with a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | For patients requesting Betaseron-approve if the patient is new to therapy and if the patient has tried generic dimethyl fumarate. Note: Prior use of brand Tecfidera, Bafiertam or Vumerity with inadequate efficacy or significant intolerance (according to the prescriber) also counts. Cont tx-approve if the patient has been established on Betaseron. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BEXAROTENE (ORAL)

Products Affected

- bexarotene

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation) |
| Coverage Duration | 3 years |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BOSENTAN/AMBRISENTAN

Products Affected

- ambrisentan

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Pulmonary arterial hypertension (PAH) WHO Group 1, results of right heart cath |
| Age Restrictions | N/A |
| Prescriber Restrictions | For treatment of pulmonary arterial hypertension, ambrisentan must be prescribed by or in consultation with a cardiologist or a pulmonologist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BOSULIF

Products Affected

- Bosulif oral tablet 100 mg, 400 mg, 500 mg

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis. For CML/ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. For ALL, prior therapies tried. |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | For CML, patient must have Ph-positive CML. For ALL, patient must have Ph-positive ALL and has tried ONE other tyrosine kinase inhibitors that are used for Philadelphia chromosome positive ALL (e.g., Gleevec, Sprycel, etc). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Philadelphia chromosome positive Acute Lymphoblastic Leukemia |
| Part B Prerequisite | No |

BRAFTOVI

Products Affected

- Braftovi oral capsule 75 mg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, BRAF V600 status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Melanoma - approve if the patient has unresectable, advanced or metastatic melanoma AND has a BRAF V600 mutation. Colon or Rectal cancer- approve if the patient meets the following (A, B, and C): A) The patient has BRAF V600E mutation-positive disease AND B) The patient has previously received a chemotherapy regimen for colon or rectal cancer AND C) The agent is prescribed as part of a combination regimen for colon or rectal cancer. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

BRUKINSA

Products Affected

- Brukinsa

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Mantle Cell Lymphoma - approve if the patient has tried at least one systemic regimen. Chronic lymphocytic leukemia/small lymphocytic lymphoma-approve. Marginal zone lymphoma-approve if the patient has tried at least one systemic regimen. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma-approve. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Chronic lymphocytic Leukemia (CLL). Small Lymphocytic Lymphoma (SLL) |
| Part B Prerequisite | No |

C1 ESTERASE INHIBITORS

Products Affected

- Cinryze

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | prescribed by or in consultation with an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders |
| Coverage Duration | 1 year |
| Other Criteria | Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II], Prophylaxis, Initial Therapy: approve if the patient has HAE type I or type II confirmed by low levels of functional C1-INH protein (less than 50 percent of normal) at baseline and lower than normal serum C4 levels at baseline. Patient is currently taking Cinryze for prophylaxis - approve if the patient meets the following criteria (i and ii): i) patient has a diagnosis of HAE type I or II, and ii) according to the prescriber, the patient has had a favorable clinical response since initiating Cinryze as prophylactic therapy compared with baseline. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CABLIVI

Products Affected

- Cablivi injection kit

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, concurrent medications |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with a hematologist |
| Coverage Duration | Approve for 12 months |
| Other Criteria | aTTP-approve if the requested medication was initiated in the inpatient setting in combination with plasma exchange therapy AND patient is currently receiving at least one immunosuppressive therapy AND if the patient has previously received Cablivi, he/she has not had more than two recurrences of aTTP while on Cablivi. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CABOMETYX

Products Affected

- Cabometyx

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, histology, RET gene rearrangement status |
| Age Restrictions | Thyroid carcinoma-12 years and older, other dx (except bone cancer)-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Renal Cell Carcinoma-Approve if the patient has relapsed or stage IV disease. Hepatocellular Carcinoma-approve if the patient has been previously treated with at least one other systemic therapy (e.g., Nexavar, Lenvima). Bone cancer-approve if the patient has Ewing sarcoma or osteosarcoma and has tried at least one previous systemic regimen. Thyroid carcinoma-approve if the patient has differentiated thyroid carcinoma, patient is refractory to radioactive iodine therapy and the patient has tried a vascular endothelial growth factor receptor (VEGFR)-targeted therapy. Endometrial carcinoma-approve if the patient has tried one systemic regimen. GIST-approve if the patient has tried two of the following- imatinib, Ayvakit, sunitinib, dasatinib, Stivarga or Qinlock. NSCLC- approve if the patient has RET rearrangement positive tumor. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Non-Small Cell Lung Cancer, Gastrointestinal stromal tumors (GIST), Bone cancer, Endometrial Carcinoma |
| Part B Prerequisite | No |

CALQUENCE

Products Affected

- Calquence
- Calquence (acalabrutinib mal)

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | <p>For all covered diagnoses-approve if the patient is currently receiving therapy with Calquence. For patients new to therapy the following criteria apply-Chronic Lymphocytic Leukemia: Approve if the patient meets one of the following (i, ii, iii, iv, or v): i. Patient has tried Imbruvica, OR ii. Patient is using or is planning to use the requested agent in combination with Gazyva (obinutuzumab intravenous infusion), OR iii. patient is at an increased risk of bleeding, OR iv. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR v. Patient has hypertension. Small Lymphocytic Lymphoma: Approve if the patient meets one of the following (i, ii, iii, iv, or v): i. Patient has tried Imbruvica, OR ii. Patient is using or is planning to use the requested agent in combination with Gazyva (obinutuzumab intravenous infusion), OR iii. patient is at an increased risk of bleeding, OR iv. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR v. Patient has hypertension. Mantle Cell Lymphoma: Approve if the patient meets one of the following (i, ii, iii, or iv): i. Patient has tried Imbruvica, OR ii. patient is at an increased risk of bleeding, OR iii. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR iv. Patient has hypertension. Marginal Zone Lymphoma: Approve if the patient meets one of the following (i, ii, iii, or iv): i. Patient has tried Imbruvica, OR ii. patient is at an increased risk of bleeding, OR iii. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial</p> |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | flutter, OR iv. Patient has hypertension. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: Approve if the patient meets one of the following (i, ii, iii, or iv): i. Patient has tried Imbruvica, OR ii. patient is at an increased risk of bleeding, OR iii. patient has atrial fibrillation/atrial flutter or is at risk of atrial fibrillation/atrial flutter, OR iv. Patient has hypertension. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Marginal zone lymphoma. |
| Part B Prerequisite | No |

CAPRELSA

Products Affected

- Caprelsa oral tablet 100 mg, 300 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | MTC - approve. DTC - approve if refractory to radioactive iodine therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Differentiated (i.e., papillary, follicular, and Hurthle) Thyroid Carcinoma. Non-Small Cell Lung Cancer with RET Gene Rearrangements |
| Part B Prerequisite | No |

CARBAGLU

Products Affected

- carglumic acid

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a metabolic disease specialist or a specialist who focuses in the treatment of metabolic diseases |
| Coverage Duration | NAGS-Pt meets criteria no genetic test - 3mo. Pt had genetic test - 12mo, other-approve 7 days |
| Other Criteria | N-Acetylglutamate synthase deficiency with hyperammonemia-Approve if genetic testing confirmed a mutation leading to N-acetylglutamate synthase deficiency or if the patient has hyperammonemia. Propionic Acidemia or Methylmalonic Acidemia with Hyperammonemia, Acute Treatment-approve if the patient's plasma ammonia level is greater than or equal to 50 micromol/L and the requested medication will be used in conjunction with other ammonia-lowering therapies. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) (generic carglumic acid) |
| Part B Prerequisite | No |

CAYSTON

Products Affected

- Cayston

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis. |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient has <i>Pseudomonas aeruginosa</i> in culture of the airway (e.g., sputum culture, oropharyngeal culture, bronchoalveolar lavage culture). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CHEMET

Products Affected

- Chemet

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Blood lead level |
| Age Restrictions | Approve in patients between the age of 12 months and 18 years |
| Prescriber Restrictions | Prescribed by or in consultation with a professional experienced in the use of chelation therapy (eg, a medical toxicologist or a poison control center specialist) |
| Coverage Duration | Approve for 2 months |
| Other Criteria | Approve if Chemet is being used to treat acute lead poisoning (not as prophylaxis) and prior to starting Chemet therapy the patient's blood lead level was greater than 45 mcg/dL. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CHENODAL

Products Affected

- Chenodal

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | For the treatment of gallstones, approve if the patient has tried or is currently using an ursodiol product. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CLOBAZAM

Products Affected

- clobazam oral suspension
- clobazam oral tablet
- Sympazan

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, other medications tried |
| Age Restrictions | 2 years and older (initial therapy) |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist (initial therapy) |
| Coverage Duration | 1 year |
| Other Criteria | Lennox-Gastaut Syndrome, initial therapy-patient has tried one of the following: lamotrigine, topiramate, rufinamide, felbamate, or Epidiolex. Treatment refractory seizures/epilepsy, initial therapy-patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs (e.g., valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, felbamate). Continuation-prescriber confirms patient is responding to therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Dravet Syndrome and treatment-refractory seizures/epilepsy |
| Part B Prerequisite | No |

COMETRIQ

Products Affected

- Cometriq oral capsule 100 mg/day(80 mg x1-20 mg x1), 140 mg/day(80 mg x1-20 mg x3), 60 mg/day (20 mg x 3/day)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis. |
| Age Restrictions | NSCLC/MTC-18 years and older, DTC-12 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | MTC - approve. Non-Small Cell Lung Cancer with RET Gene Rearrangements - approve. Differentiated (i.e., papillary, follicular, and Hurthle) Thyroid Carcinoma-approve if the patient's carcinoma is refractory to radioactive iodine therapy and patient has tried a Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Non-Small Cell Lung Cancer with RET Gene Rearrangements, Differentiated (i.e., papillary, follicular, and Hurthle) Thyroid Carcinoma |
| Part B Prerequisite | No |

COPIKTRA

Products Affected

- Copiktra

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | For all covered diagnoses-approve if the patient is currently receiving therapy with Copiktra. For patients new to therapy the following criteria apply-Chronic Lymphocytic Leukemia: Approve if the patient meets one of the following (i, ii, iii iv, or v): i. Patient has tried Imbruvica (Note: A trial of another BTK inhibitor AND Venclexta also counts), OR ii. patient is at an increased risk of bleeding, OR iii. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR iv. Patient has hypertension, OR v. Patient has experienced or is at increased risk for secondary primary malignancies. (Note: An example is skin cancer). Small Lymphocytic Lymphoma: Approve if the patient meets one of the following (i, ii, iii, iv, or v): i. Patient has tried Imbruvica (Note: A trial of another BTK inhibitor AND Venclexta also counts), OR ii. patient is at an increased risk of bleeding, iii. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR iv. Patient has hypertension, OR v. Patient has experienced or is at increased risk for secondary primary malignancies. (Note: An example is skin cancer). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

COTELLIC

Products Affected

- Cotellic

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Melanoma initial - must have BRAF V600 mutation. |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | <p>Melanoma (unresectable, advanced or metastatic) - being prescribed in combination with Zelboraf. CNS Cancer-approve if the patient has BRAF V600 mutation-positive disease AND medication is being used for one of the following situations (i, ii, or iii): i) Adjuvant treatment of pilocytic astrocytoma or pleomorphic xanthoastrocytoma or ganglioglioma, OR ii) recurrent disease for low-grade glioma or anaplastic glioma or glioblastoma, OR iii) melanoma with brain metastases AND medication will be taken in combination with Zelboraf (vemurafenib tablets).</p> <p>Histiocytic Neoplasm-approve if the patient meets one of the following (i, ii, or iii): i) patient has Langerhans cell histiocytosis and one of the following: multisystem disease or pulmonary disease or central nervous system lesions, OR ii) patient has Erdheim Chester disease, OR iii) patient has Rosai-Dorfman disease AND patient has BRAF V600 mutation-positive disease.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Central Nervous System Cancer, Histiocytic Neoplasm |
| Part B Prerequisite | No |

CRESEMBA (ORAL)

Products Affected

- Cresemba oral

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 months |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Candidiasis of the esophagus - HIV infection, sepsis |
| Part B Prerequisite | No |

CYSTEAMINE (OPHTHALMIC)

Products Affected

- Cystaran

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an ophthalmologist or a metabolic disease specialist or specialist who focuses in the treatment of metabolic diseases |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient has corneal cysteine crystal deposits confirmed by slit-lamp examination |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

CYSTEAMINE (ORAL)

Products Affected

- Cystagon

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Concomitant use of Cystagon and Procysbi |
| Required Medical Information | Diagnosis, genetic tests and lab results (as specified in the Other Criteria field) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a nephrologist or a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases) |
| Coverage Duration | 1 year |
| Other Criteria | Cystinosis, nephropathic-approve if the prescriber confirms the diagnosis was confirmed by genetic testing confirming a mutation of the CTNS gene OR white blood cell cystine concentration above the upper limit of the normal reference range for the reporting laboratory. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DALFAMPRIDINE

Products Affected

- dalfampridine

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older (initial and continuation therapy) |
| Prescriber Restrictions | MS. If prescribed by, or in consultation with, a neurologist or MS specialist (initial and continuation). |
| Coverage Duration | Initial-4months, Continuation-1 year. |
| Other Criteria | Initial-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has impaired ambulation as evaluated by an objective measure (e.g., timed 25 foot walk and multiple sclerosis walking scale-12). Continuation-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has responded to or is benefiting from therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DALIRESP

Products Affected

- Daliresp
- roflumilast

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Chronic Obstructive Pulmonary Disease (COPD), medications tried. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | COPD, approve in patients who meet all of the following conditions: Patients has severe COPD or very severe COPD, AND Patient has a history of exacerbations, AND Patient has tried a medication from two of the three following drug categories: long-acting beta2-agonist (LABA) [eg, salmeterol, indacaterol], long-acting muscarinic antagonist (LAMA) [eg, tiotropium], inhaled corticosteroid (eg, fluticasone). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DAURISMO

Products Affected

- Daurismo oral tablet 100 mg, 25 mg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, medications that will be used in combination, comorbidities |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | AML - approve if Daurismo will be used in combination with cytarabine. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DEFERASIROX

Products Affected

- deferasirox oral tablet

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Serum ferritin level |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a hematologist |
| Coverage Duration | 1 year |
| Other Criteria | Transfusion-related chronic iron overload, initial therapy - approve if the patient is receiving blood transfusions at regular intervals for various conditions (eg, thalassemia syndromes, myelodysplastic syndrome, chronic anemia, sickle cell disease) AND prior to starting therapy, the serum ferritin level is greater than 1,000 mcg/L. Non-transfusion-dependent thalassemia syndromes chronic iron overload, initial therapy - approve if prior to starting therapy the serum ferritin level is greater than 300 mcg/L. Continuation therapy - approve if the patient is benefiting from therapy as confirmed by the prescribing physician. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DEFERIPRONE

Products Affected

- deferiprone

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Serum ferritin level |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a hematologist |
| Coverage Duration | 1 year |
| Other Criteria | Iron overload, chronic-transfusion related due to thalassemia syndrome or related to sickle cell disease or other anemias-Initial therapy - approve. Continuation therapy - approve is the patient is benefiting from therapy as confirmed by the prescribing physician. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DIACOMIT

Products Affected

- Diacomit

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of diagnosis. |
| Age Restrictions | 6 months and older (initial therapy) |
| Prescriber Restrictions | Prescribed by or in consultation with an neurologist (initial therapy) |
| Coverage Duration | 1 year |
| Other Criteria | Dravet Syndrome-Initial therapy-approve if the patient is concomitantly receiving clobazam or is unable to take clobazam due to adverse events. Dravet Syndrome-Continuation-approve if the patient is responding to therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DIMETHYL FUMARATE

Products Affected

- dimethyl fumarate oral capsule, delayed release (DR/EC) 120 mg, 120 mg (14)- 240 mg (46), 240 mg

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agents used for multiple sclerosis (MS). |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist or MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

DUPIXENT

Products Affected

- Dupixent Pen subcutaneous pen injector 200 mg/1.14 mL, 300 mg/2 mL
- Dupixent Syringe subcutaneous syringe 100 mg/0.67 mL, 200 mg/1.14 mL, 300 mg/2 mL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with Xolair or another Anti-interleukin (IL) Monoclonal Antibody. |
| Required Medical Information | Diagnosis, prescriber specialty, other medications tried and length of trials |
| Age Restrictions | AD-6 months and older, asthma-6 years of age and older, Esophagitis-12 and older, Chronic Rhinosinusitis/Prurigo nodularis-18 and older |
| Prescriber Restrictions | Atopic Dermatitis/prurigo nodularis-Prescribed by or in consultation with an allergist, immunologist or dermatologist, asthma-prescribed by or in consultation with an allergist, immunologist or pulmonologist. Rhinosinusitis-prescribed by or in consultation with an allergist, immunologist or otolaryngologist. Esophagitis-presc/consult-allergist or gastro |
| Coverage Duration | AD-Init-4mo, Cont-1 yr, asthma/Rhinosinusitis/esophagitis/prurigo nod-init-6 mo, cont 1 yr |
| Other Criteria | AD,Init-pt 2yrs and older-pt meets a and b:a.used at least 1 med,med-high,high, and/or super-high-potency rx top CS OR AD affecting ONLY face,eyes/lids,skin folds,and/or genitalia and tried tacrolimus oint AND b.Inadeq efficacy was demonstrated w/prev tx.AD,Init-pt between 6 mo and less than 2 yr-pt meets a and b:a.used at least 1 med,med-high,high, and/or super-high-potency rx top CS and b.inadeq efficacy was demonstrated w/prev tx OR AD affecting ONLY face,eyes/lids,skin folds,and/or genitalia.Cont-pt responded to Dupixent.Asthma,init-pt meets (i, ii, and iii):i.Pt meets (a or b):a)blood eosinophil greater than or equal to 150 cells per microliter w/in prev 6 wks or within 6 wks prior to tx with any IL tx or Xolair OR b)has oral CS-dependent asthma, AND ii.received combo tx w/following (a and b): a)ICS AND b)1 add asthma control/maint med(NOTE:exception to the requirement for a trial of 1 add asthma controller/maint med can be made if pt already received anti-IL-5 tx or Xolair used concomitantly w/an ICS AND iii.asthma uncontrolled or was |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>uncontrolled prior to starting anti-IL tx or Xolair defined by 1 (a, b, c, d or e): a)exper 2 or more asthma exacer req tx with systemic CS in prev yr OR b)exper 1 or more asthma exacer requiring hosp or ED visit in prev yr OR c)FEV1 less than 80percent predicted OR d)FEV1/FVC less than 0.80 OR e)asthma worsens w/tapering of oral CS tx. Cont-pt meets (i and ii): i.cont to receive tx with 1 ICS or 1 ICS-containing combo inhaler AND ii.has responded to Dupixent. Chronic rhinosinusitis w/nasal polyposis, init-pt receiving tx with an intranasal CS and experi rhinosinusitis symptoms like nasal obstruction, rhinorrhea, or reduction/loss of smell AND meets 1 (a or b): a)received tx w/syst CS w/in prev 2 yrs or has contraindication to systemic CS tx OR b)prior surgery for nasal polyps. Cont-pt cont to receive tx with an intranasal CS and responded to Dupixent. Eosino esoph, init-weighs greater than or equal to 40 kg, has dx of eosino esophagitis confirmed by endoscopic biopsy demonstrating greater than or equal to 15 intraepithelial eosinophils per high-power field, and does not have a secondary cause of eosino esophagitis, and has received at least 8 wks of tx with a Rx strength PPI. Cont-pt received at least 6mo of tx with Dupixent and has experi reduced intraepithelial eosinophil count or decreased dysphagia/pain upon swallowing or reduced frequency/severity of food impaction. Prurigo Nod, init-pt has greater than or equal to 20 nodular lesions and pt has experienced pruritus at least 6 wks, AND pt tried at least 1 high- or super-high-potency Rx topical CS. Cont-pt received at least 6 mo of tx with Dupixent and has experi reduced nodular lesion count, decreased pruritis or reduced nodular lesion size.</p> |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

EMGALITY

Products Affected

- Emgality Pen
- EMGALITY SUBCUTANEOUS SYRINGE 120 MG/ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Combination therapy with Aimovig, Vyepti or Ajovy |
| Required Medical Information | Diagnosis, number of migraine or cluster headaches per month, prior therapies tried |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Cluster headache tx-6 months, migraine prevention-1 year |
| Other Criteria | Migraine headache prevention-Approve if the patient meets the following criteria (A and B): A) Patient has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication), AND B) Patient has tried at least one standard prophylactic pharmacologic therapy (e.g., anticonvulsant, beta-blocker), and has had inadequate response or the patient has a contraindication to other prophylactic pharmacologic therapies according to the prescribing physician. Episodic cluster headache treatment-approve if the patient has between one headache every other day and eight headaches per day. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ENBREL

Products Affected

- Enbrel Mini
- Enbrel subcutaneous solution
- Enbrel subcutaneous syringe
- Enbrel SureClick

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with biologic therapy or targeted synthetic DMARD |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried. |
| Age Restrictions | PP-4 years and older (initial therapy) |
| Prescriber Restrictions | Initial-RA/AS/JIA/JRA,prescribed by or in consult w/ rheumatologist. PsA, prescribed by or in consultation w/ rheumatologist or dermatologist. PP, prescribed by or in consult w/ dermatologist.GVHD,prescribed by or in consult w/ oncologist,hematologist,or physician affiliated w/ transplant center.Behcet's disease,prescribed by or in consult w/ rheumatologist,dermatologist,ophthalmologist,gastroenterologist,or neurologist. |
| Coverage Duration | Approve through 12/31/23 |
| Other Criteria | RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). JIA/JRA, approve if the pt has aggressive disease, as determined by the prescriber, or the pt has tried one other systemic therapy for this condition (eg, MTX, sulfasalazine, leflunomide, NSAID), biologic or the pt will be started on Enbrel concurrently with MTX, sulfasalazine, or leflunomide or the pt has an absolute contraindication to MTX (eg, pregnancy, breast feeding, alcoholic liver disease, immunodeficiency syndrome, blood dyscrasias), sulfasalazine, or leflunomide.Plaque psoriasis (PP) initial approve if the patient meets one of the following conditions: 1) patient has tried at least one traditional systemic agent for at least 3 months for plaque psoriasis, unless intolerant (eg, MTX, cyclosporine, Soriatane, oral methoxsalen plus PUVA, (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) the patient has a contraindication to one oral agent for psoriasis such |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>as MTX. GVHD-approve. Behcet's. Has tried at least 1 conventional tx (eg, systemic corticosteroid, immunosuppressant, interferon alfa, MM, etc) or adalimumab or infliximab. RA/AS/JIA/PP/PsA Cont - must have a response to tx according to the prescriber. Behcet's, GVHD Cont-if the patient has had a response to tx according to the prescriber. Clinical criteria incorporated into the Enbrel 25 mg quantity limit edit, approve additional quantity (to allow for 50 mg twice weekly dosing) if one of the following is met: 1) Patient has plaque psoriasis, OR 2) Patient has RA/JIA/PsA/AS and is started and stabilized on 50 mg twice weekly dosing, OR 3) Patient has RA and the dose is being increased to 50 mg twice weekly and patient has taken MTX in combination with Enbrel 50 mg once weekly for at least 2 months, unless MTX is contraindicated or intolerant, OR 4) Patient has JIA/PsA/AS and the dose is being increased to 50 mg twice weekly after taking 50 mg once weekly for at least 2 months.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Graft versus host disease (GVHD), Behcet's disease |
| Part B Prerequisite | No |

EPCLUSA

Products Affected

- Epclusa oral pellets in packet 150-37.5 mg, 200-50 mg
- Epclusa oral tablet 200-50 mg, 400-100 mg

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with other direct acting antivirals, excluding ribavirin. |
| Required Medical Information | Genotype, prescriber specialty, other medications tried or used in combination with requested medication |
| Age Restrictions | 3 years or older |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician |
| Coverage Duration | Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug |
| Other Criteria | Criteria will be applied consistent with current AASLD/IDSA guidance. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Indications consistent with current AASLD/IDSA guidance |
| Part B Prerequisite | No |

EPIDIOLEX

Products Affected

- Epidiolex

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous therapies |
| Age Restrictions | Patients 1 year and older (initial therapy) |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist (initial therapy) |
| Coverage Duration | 1 year |
| Other Criteria | Dravet Syndrome-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs or if the patient has tried or is concomitantly receiving one of Diacomit or clobazam or Fintepla. Lennox Gastaut Syndrome-approve if the patient has tried or is concomitantly receiving at least two other antiepileptics drugs. Tuberous Sclerosis Complex-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs. Continuation of therapy-approve if the patient is responding to therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

EPOETIN ALFA

Products Affected

- Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | CRF anemia in patients not on dialysis. Hemoglobin (Hb) of less than 10.0 g/dL for adults or less than or equal to 11 g/dL for children to start. Hb less than or equal to 11.5 g/dL for adults or 12 g/dL or less for children if previously on epoetin alfa, Mircera or Aranesp. Anemia w/myelosuppressive chemotx. pt must be currently receiving myelosuppressive chemo and Hb 10.0 g/dL or less to start. Hb less than or equal to 12.0 g/dL if previously on epoetin alfa or Aranesp. MDS, approve if Hb is 10 g/dL or less or serum erythropoietin level is 500 mU/mL or less to start. Previously receiving Aranesp or EA, approve if Hb is 12.0 g/dL or less. Anemia in HIV with zidovudine, Hb is 10.0 g/dL or less or endogenous erythropoietin levels are 500 mU/mL or less at tx start. Previously on EA approve if Hb is 12.0 g/dL or less. Surgical pts to reduce RBC transfusions - Hgb is less than or equal to 13, surgery is elective, nonvascular and non-cardiac and pt is unwilling or unable to donate autologous blood prior to surgery |
| Age Restrictions | MDS anemia = 18 years of age and older |
| Prescriber Restrictions | MDS anemia/myelofibrosis, prescribed by or in consultation with, a hematologist or oncologist. |
| Coverage Duration | Chemo-6m, Transfus-1m, Myelofibrosis-init-3 mo, cont-1 yr, all others-1 yr |
| Other Criteria | Myelofibrosis-Initial-patient has a Hb less than 10 or serum erythropoietin less than or equal to 500 Mu/mL. Cont-approve if according to the prescriber the patient has had a response. Anemia in patients with chronic renal failure on dialysis - deny under Medicare Part D (claim should be submitted under the ESRD bundled payment benefit). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Anemia due to myelodysplastic syndrome (MDS), Myelofibrosis |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

ERIVEDGE

Products Affected

- Erivedge

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | BCC (La or Met) - must not have had disease progression while on Odomzo. |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years |
| Other Criteria | Locally advanced basal cell carcinoma (LABCC), approve if 1. the patient's BCC has recurred following surgery or radiation, OR 2. the patient is not a candidate for surgery and radiation therapy. Central nervous system cancer (this includes brain and spinal cord tumors)-approve if the patient has tried at least one chemotherapy agent and according to the prescriber, the patient has a mutation of the sonic hedgehog pathway. Basal cell carcinoma, metastatic-approve. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Central nervous System Cancer |
| Part B Prerequisite | No |

ERLEADA

Products Affected

- Erleada

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Prostate cancer-non-metastatic, castration resistant and prostate cancer-metastatic, castration sensitive-approve if the requested medication will be used in combination with a gonadotropin-releasing hormone (GnRH) agonist or the medication is concurrently used with Firmagon or if the patient has had a bilateral orchiectomy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ERLOTINIB

Products Affected

- erlotinib oral tablet 100 mg, 150 mg, 25 mg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Advanced or Metastatic NSCLC, approve if the patient has sensitizing EGFR mutation positive non-small cell lung cancer as detected by an approved test. Note-Examples of sensitizing EGFR mutation-positive non-small cell lung cancer include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. RCC, approve if the patient has recurrent or advanced non-clear cell histology RCC or if the patient had hereditary leiomyomatosis and renal cell carcinoma and erlotinib will be used in combination with bevacizumab. Bone cancer-chordoma-approve if the patient has chordoma and has tried at least one previous therapy. Pancreatic cancer-approve if the medication is used in combination with gemcitabine and if the patient has locally advanced, metastatic or recurrent disease. Vulvar cancer-approve if the patient has advanced, recurrent or metastatic disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Renal Cell Carcinoma, vulvar cancer and Bone Cancer-Chordoma. |
| Part B Prerequisite | No |

ESBRIET

Products Affected

- Esbriet oral capsule
- pirfenidone oral tablet 267 mg, 801 mg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist |
| Coverage Duration | 1 year |
| Other Criteria | IPF - must have FVC greater than or equal to 40 percent of the predicted value AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

EVEROLIMUS

Products Affected

- everolimus (antineoplastic) oral tablet
- everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Breast Cancer-HER2 status, hormone receptor (HR) status. |
| Age Restrictions | All dx except TSC associated SEGA or partial onset seizures-18 years and older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | <p>Breast Cancer-approve if pt meets ALL the following (A, B, C, D, E, and F):A)pt has recurrent or metastatic,HR+ disease AND B)pt has HER2-negative breast cancer AND C)pt has tried at least 1 prior endocrine therapy AND D)pt meets 1 of the following conditions (i or ii):i.pt is a postmenopausal woman or man OR ii.pt is pre/perimenopausal woman AND is receiving ovarian suppression/ablation with a GnRH agonist, or has had surgical bilateral oophorectomy or ovarian irradiation AND E)pt meets 1 of the following conditions (i or ii): i. Afinitor will be used in combo with exemestane and pt meets 1 of the following:pt is male and is receiving a GnRH analog or pt is a woman or ii. Afinitor will be used in combo with fulvestrant or tamoxifen AND F)pt has not had disease progression while on Afinitor. RCC, relapsed or Stage IV disease-approve if using for non-clear cell disease or if using for clear cell disease, pt has tried 1 prior systemic therapy (e.g., Inlyta, Votrient, Sutent, Cabometyx, Nexavar).TSC Associated SEGA-approve if pt requires therapeutic intervention but cannot be curatively resected. Thymomas and Thymic Carcinomas-approve if pt has tried chemotherapy or cannot tolerate chemotherapy. TSC associated renal angiomyolipoma -approve. WM/LPL - approve if pt has progressive or relapsed disease or if pt has not responded to primary therapy. Thyroid Carcinoma, differentiated-approve</p> |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>if pt is refractory to radioactive iodine therapy. Endometrial Carcinoma-approve if Afinitor will be used in combo with letrozole. GIST-approve if pt has tried 2 of the following drugs: Sutent, Sprycel, Stivarga, Ayvakit, Qinlock or imatinib AND there is confirmation that Afinitor will be used in combo with 1 of these drugs (Sutent, Stivarga, or imatinib) in the treatment of GIST. TSC-associated partial-onset seizures-approve. NET tumors of the pancreas, GI Tract, Lung and Thymus (carcinoid tumors)-approve. Meningioma-approve if pt has recurrent or progressive disease. Soft tissue sarcoma-approve if pt has perivascular epitheloid cell tumors (PE Coma) or recurrent angiomyolipoma/lymphangiomyomatosis. Classic hodgkin lymphoma-approve if pt has relapsed or refractory disease. Histiocytic neoplasm-approve if pt has Erdheim-Chester disease or, Rosai-Dorfman disease or Langerhans cell histiocytosis with bone disease, central nervous system lesions, multisystem disease or pulmonary disease. Patient must also have PIK3CA mutation.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | <p>neuroendocrine tumors of the thymus (Carcinoid tumors). Soft tissue sarcoma, classical Hodgkin lymphoma, Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL), Thymomas and Thymic carcinomas, Differentiated Thyroid Carcinoma, Endometrial Carcinoma, Gastrointestinal Stromal Tumors (GIST), Meningioma, men with breast cancer, pre/peri-menopausal women with breast cancer, Histiocytic Neoplasm</p> |
| Part B Prerequisite | No |

EXKIVITY

Products Affected

- Exkivity

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Non-Small Cell Lung Cancer (NSCLC)-approve if the patient meets (A, B and C): A) Patient has locally advanced or metastatic NSCLC AND B) Patient has epidermal growth factor receptor (EGFR) exon 20 insertion mutation, as determined by an approved test AND C) Patient has previously tried at least one platinum-based chemotherapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FINTEPLA

Products Affected

- Fintepla

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 2 years and older (initial therapy) |
| Prescriber Restrictions | Prescribed by or in consultation with an neurologist (initial therapy) |
| Coverage Duration | 1 year |
| Other Criteria | Dravet Syndrome-Initial therapy-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs or patient has tried or is concomitantly receiving Epidiolex, Clobazam or Diacomit. Dravet Syndrome-Continuation-approve if the patient is responding to therapy. Lennox-Gastaut Syndrome, initial-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs. Lennox-Gastaut Syndrome, continuation-approve if the patient is responding to therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

FOTIVDA

Products Affected

- Fotivda

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, other therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years |
| Other Criteria | Renal Cell Carcinoma (RCC)-approve if the patient has relapsed or Stage IV disease and has tried at least two other systemic regimens. Note: Examples of systemic regimens for renal cell carcinoma include axitinib tablets, axitinib + pembrolizumab injection, cabozantinib tablets, cabozantinib + nivolumab injection, sunitinib malate capsules, pazopanib tablets, sorafenib tablets, and lenvatinib capsules + everolimus. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GATTEX

Products Affected

- Gattex 30-Vial

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 1 year and older |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist (initial and continuation) |
| Coverage Duration | 1 year |
| Other Criteria | Initial-approve if the patient is currently receiving parenteral nutrition on 3 or more days per week or according to the prescriber, the patient is unable to receive adequate total parenteral nutrition required for caloric needs. Continuation-approve if the patient has experienced improvement. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GAVRETO

Products Affected

- Gavreto

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | NSCLC-18 years and older, MTC/thyroid cancer-12 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | NSCLC-approve if the patient has metastatic disease and rearranged during transfection (RET) fusion-positive disease detected by an Food and Drug Administration (FDA) approved test. Medullary thyroid cancer (MTC)-approve if the patient has advanced or metastatic rearranged during transfection (RET)-mutant disease and the disease requires treatment with systemic therapy. Thyroid cancer (other than MTC)-approve if the patient has advanced or metastatic rearranged during transfection (RET) fusion-positive disease, the disease is radioactive iodine-refractory AND the disease requires treatment with systemic therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GILENYA

Products Affected

- fingolimod

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with other disease-modifying agents used for multiple sclerosis (MS). |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by, or in consultation with, a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Initial treatment-approve if the patient has tried generic dimethyl fumarate, unless the patient meets one of the following: a)patient is greater than or equal to 10 years of age but less than 18 years old or, b) if the patient has highly active or aggressive multiple sclerosis defined as, rapidly advancing deterioration in physical functioning (Note: examples include loss of mobility or lower levels of ambulation, severe changes in strength or coordination), or c) disabling relapse with suboptimal response to systemic corticosteroids, or d) Magnetic resonance imaging (MRI) findings suggest highly active or aggressive multiple sclerosis (Note: Examples include new, enlarging, or a high burden of T2 lesions or gadolinium-enhancing lesions) or, e) manifestation of multiple sclerosis-related cognitive impairment. Note: Prior use of brand Tecfidera, Bafiertam, Vumerity or a glatiramer product (brand or generic) with inadequate efficacy or significant intolerance (according to the prescriber) also counts. Cont tx - approve if the patient has been established on requested medication. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GILOTRIF

Products Affected

- Gilotrif

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For NSCLC - EGFR exon deletions or mutations or if NSCLC is squamous cell type |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | NSCLC EGFR pos - For the treatment of advanced or metastatic non small cell lung cancer (NSCLC)-approve if the patient has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: examples of sensitizing EGFR mutation-positive NSCLC include the following mutations : exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. NSCLC metastatic squamous cell must have disease progression after treatment with platinum based chemotherapy. Head and neck cancer-approve if the patient has non-nasopharyngeal head and neck cancer and the patient has disease progression on or after platinum based chemotherapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Head and neck cancer |
| Part B Prerequisite | No |

GLATIRAMER

Products Affected

- glatiramer subcutaneous syringe 20 mg/mL, 40 mg/mL
- Glatopa subcutaneous syringe 20 mg/mL, 40 mg/mL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with other disease-modifying agent used for multiple sclerosis |
| Required Medical Information | Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or after consultation with a neurologist or an MS specialist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GLUCAGON-LIKE PEPTIDE-1 AGONISTS

Products Affected

- Bydureon BCise
- Byetta subcutaneous pen injector 10 mcg/dose(250 mcg/mL) 2.4 mL, 5 mcg/dose (250 mcg/mL) 1.2 mL
- Trulicity

| PA Criteria | Criteria Details |
|------------------------------|----------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

GONADOTROPIN-RELEASING HORMONE AGONISTS - INJECTABLE LONG ACTING

Products Affected

- leuprolide subcutaneous kit
- Lupron Depot
- Lupron Depot (3 month)
- Lupron Depot (4 month)
- Lupron Depot (6 Month)

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prostate cancer-prescr/consult with oncologist or urologist. For the treatment of other cancer diagnosis must be prescribed by or in consultation with an oncologist. |
| Coverage Duration | uterine leiomyomata 3 mo.All other=12 mo |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Ovarian cancer, breast cancer, prophylaxis or treatment of uterine bleeding or menstrual suppression in patients with hematologic malignancy or undergoing cancer treatment or prior to bone marrow/stem cell transplantation, head and neck cancer-salivary gland tumors |
| Part B Prerequisite | No |

GROWTH HORMONES

Products Affected

- Omnitrope

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | <p>GHD in Children/Adolescents. Pt meets one of the following-1-had 2 GH stim tests with the following-levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon and both are inadequate as defined by a peak GH response which is below the normal reference range of the testing laboratory OR had at least 1 GH test and results show inadequate response and has at least one risk factor for GHD (e.g., ht for age curve deviated down across 2 major height percentiles [e.g., from above the 25 percentile to below the 10 percentile], growth rate is less than the expected normal growth rate based on age and gender, low IGF-1 and/or IGFBP-3 levels).</p> <p>2.brain radiation or tumor resection and pt has 1 GH stim test and results is inadequate response or has def in at least 1 other pituitary hormone (that is, ACTH, TSH, gonadotropin deficiency [LH and/or FSH] are counted as 1 def], or prolactin).</p> <p>3. congenital hypopituitarism and has one GH stim test with inadequate response OR def in at least one other pituitary hormone and/or the patient has the imaging triad of ectopic posterior pituitary and pituitary hypoplasia with abnormal pituitary stalk</p> <p>4.pt has panhypopituitarism and has pituitary stalk agenesis, empty sella, sellar or supra-sellar mass lesion, or ectopic posterior pituitary bright spot on MRI or CT or pt has 3 or more pituitary hormone deficiencies or pt has had one GH test and results were inadequate</p> <p>5.pt had a hypophysectomy. Cont-pt responding to therapy</p> |
| Age Restrictions | ISS 5 y/o or older, SGA 2 y/o or older, SBS 18 y/o or older |
| Prescriber Restrictions | GHD (Initial tx children or adolescents w/o hypophysectomy), GHD adults or transitional adolescents, Noonan (initial), Prader Willi (initial for child/adult and cont tx in adults), SHOX (initial), SGA (initial) - prescribed by or in consultation with an endocrinologist. CKD (initial) endocrinologist or nephrologist. |
| Coverage Duration | ISS - 6 mos initial, 12 months cont tx, SBS-1 month, others 12 mos |

| PA Criteria | Criteria Details |
|----------------|--|
| Other Criteria | <p>GHD initial in adults and adolescents 1. endocrine must certify not being prescribed for anti-aging or to enhance athletic performance, 2. has either childhood onset or adult onset resulting from GHD alone, multiple hormone deficiency from pituitary dx, hypothalamic dz, pituitary surgery, cranial radiation tx, tumor treatment, TBI or subarachnoid hemorrhage, AND 3. meets one of the following - A. has known mutations, embryonic lesions, congenital or genetic defects or structural hypothalamic pituitary defects, B. 3 or more pituitary hormone def (ACTH, TSH, LH/FSH, or prolactin, IGF1 less than 84 mcg/L (Esoterix RIA), AND other causes of low serum IGF-1 have been excluded, C. Neg response to ONE preferred GH stim test (insulin peak response less than or equal to 5 mcg/L, Glucagon peak less than or equal to 3 mcg/L (BMI is less than or equal to 25), less than or equal to 3 and BMI is greater than or equal to 25 and less than or equal to 30 with a high pretest probability of GH deficiency, less than or equal to 1 and BMI is greater than or equal to 25 and less than or equal to 30 with a low pretest probability of GH deficiency or less than or equal to 1 mcg/L (BMI is greater than 30), if insulin and glucagon contraindicated then Arginine alone test with peak of less than or equal to 0.4 mcg/L, or Macrilen peak less than 2.8 ng/ml AND BMI is less than or equal to 40 AND if a transitional adolescent must be off tx for at least one month before retesting. Cont tx - endocrine must certify not being prescribed for anti-aging or to enhance athletic performance. ISS initial - baseline ht less than the 1.2 percentile or a standard deviation score (SDS) less than -2.25 for age and gender, open epiphyses, does not have CDGP and height velocity is either growth rate (GR) is a. less than 4 cm/yr for pts greater than or equal to 5 or b. growth velocity is less than 10th percentile for age/gender. Cont tx - prescriber confirms response to therapy. CKD initial - CKD defined by abnormal CrCl. Noonan initial - baseline height less than 5th percentile. PW cont tx in adults or adolescents who don't meet child requir - physician certifies not being used for anti-aging or to enhance athletic performance. SHOX initial - SHOX def by chromo analysis, open epiphyses, height less than 3rd percentile for age/gender. SGA initial -baseline ht less than 5th percentile for age/gender and born SGA (birth weight/length that is more than 2 SD below mean for gestational age/gender and didn't have sufficient catch up growth by 2-4 y/o). Cont tx - prescriber confirms response to therapy. Cont Tx for CKD, Noonan, PW in child/adolescents, SHOX, and TS - prescriber confirms response to therapy. SBS initial pt receiving specialized nutritional support. Cont tx - 2nd course if pt responded to tx with a decrease in the requirement for specialized nutritional support.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | SHOX, Noonan Syndrome, CKD, SBS |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

HARVONI

Products Affected

- Harvoni oral pellets in packet 33.75-150 mg, 45-200 mg
- Harvoni oral tablet 90-400 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Combination use with other direct acting antivirals, excluding ribavirin |
| Required Medical Information | N/A |
| Age Restrictions | 3 years or older |
| Prescriber Restrictions | Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD |
| Coverage Duration | Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug |
| Other Criteria | Criteria will be applied consistent with current AASLD/IDSA guidance. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Indications consistent with current AASLD/IDSA guidance |
| Part B Prerequisite | No |

HETLIOZ

Products Affected

- HetlioZ

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Non-24-patient is totally blind with no perception of light |
| Age Restrictions | Non-24-18 years or older (initial and continuation), SMS-16 years and older |
| Prescriber Restrictions | prescribed by, or in consultation with, a neurologist or a physician who specializes in the treatment of sleep disorders (initial and continuation) |
| Coverage Duration | 6 mos initial, 12 mos cont |
| Other Criteria | Initial - patient is totally blind with no perception of light, dx of Non-24 is confirmed by either assessment of one physiologic circadian phase marker (e.g., measurement of urinary melatonin levels, dim light melatonin onset, assessment of core body temperature), or if assessment of physiologic circadian phase marker cannot be done, the diagnosis must be confirmed by actigraphy plus evaluation of sleep logs. Cont - Approve if patient is totally blind with no perception of light and pt has achieved adequate results with HetlioZ therapy according to the prescribing physician (e.g., entrainment, clinically meaningful or significant increases in nighttime sleep, clinically meaningful or significant decreases in daytime sleep). Nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)-approve. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS - BENZODIAZEPINES

Products Affected

- clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg
- Diazepam Intensol
- diazepam oral solution 5 mg/5 mL (1 mg/mL)
- diazepam oral tablet
- Lorazepam Intensol
- lorazepam oral tablet 0.5 mg, 1 mg, 2 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Procedure-related sedation = 1mo. All other conditions = 12 months. |
| Other Criteria | All medically accepted indications other than insomnia, approve if the physician has assessed risk versus benefit in using the High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. Insomnia, may approve lorazepam if the patient has had a trial with two of the following: ramelteon, doxepin 3mg or 6 mg, eszopiclone, zolpidem, or zaleplon and the physician has assessed risk versus benefit in using the HRM in this patient and has confirmed that he/she would still like initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS - BENZTROPINE

Products Affected

- benztropine oral

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | For all medically-accepted indications, approve if the prescriber confirms he/she has assessed risk versus benefit in prescribing benztropine for the patient and he/she would still like to initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS - CYCLOBENZAPRINE

Products Affected

- cyclobenzaprine oral tablet 10 mg, 5 mg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | Patients aged less than 65 years, approve. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | The physician has assessed risk versus benefit in using this High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS - FIRST GENERATION ANTIHISTAMINES

Products Affected

- hydroxyzine HCl oral tablet
- promethazine oral

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | For hydroxyzine hydrochloride, authorize use without a previous drug trial for all FDA-approved indications other than anxiety. Approve hydroxyzine hydrochloride if the patient has tried at least two other FDA-approved products for the management of anxiety. Prior to approval of promethazine and hydroxyzine, approve if the physician must have assessed risk versus benefit in prescribing the requested HRM for the patient and must confirm that he/she would still like to initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS - PHENOBARBITAL

Products Affected

- phenobarbital

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | Coverage is not provided for use in sedation/insomnia. |
| Required Medical Information | N/A |
| Age Restrictions | Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | For the treatment of seizures, approve only if the patient is currently taking phenobarbital. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HIGH RISK MEDICATIONS- ESTROGENS

Products Affected

- Amabelz
- Dotti
- estradiol oral
- estradiol transdermal patch semiweekly
- estradiol transdermal patch weekly
- estradiol-norethindrone acet
- Fyavolv
- Jinteli
- Lyllana
- Menest
- Mimvey
- norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Previous medication use |
| Age Restrictions | Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months |
| Other Criteria | For the treatment of Vulvar Vaginal Atrophy, approve if the patient has had a trial of one of the following for vulvar vaginal atrophy (brand or generic): Estradiol Vaginal Cream or estradiol valerate. For prophylaxis of Postmenopausal Osteoporosis, approve if the patient has had a trial of one of the following (brand or generic): alendronate, ibandronate, risidronate or Raloxifene. The physician has assessed risk versus benefit in using this High Risk medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HUMIRA

Products Affected

- Humira Pen
- Humira Pen Crohns-UC-HS Start
- Humira Pen Psor-Uveits-Adol HS
- Humira subcutaneous syringe kit 40 mg/0.8 mL
- Humira(CF) Pedi Crohns Starter subcutaneous syringe kit 80 mg/0.8 mL, 80 mg/0.8 mL-40 mg/0.4 mL
- Humira(CF) Pen Crohns-UC-HS
- Humira(CF) Pen Pediatric UC
- Humira(CF) Pen Psor-Uv-Adol HS
- Humira(CF) Pen subcutaneous pen injector kit 40 mg/0.4 mL, 80 mg/0.8 mL
- Humira(CF) subcutaneous syringe kit 10 mg/0.1 mL, 20 mg/0.2 mL, 40 mg/0.4 mL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with another biologic DMARD or targeted synthetic DMARD. |
| Required Medical Information | Diagnosis, concurrent medications, previous therapies tried |
| Age Restrictions | Crohn's disease (CD), 6 or older (initial therapy only). Ulcerative colitis (UC), 5 years and older (initial therapy), PP-18 or older (initial therapy only). |
| Prescriber Restrictions | Initial therapy only for all dx-RA/JIA/JRA/Ankylosing spondylitis, prescribed by or in consultation with rheumatologist. Psoriatic arthritis (PsA), prescribed by or in consultation with a rheumatologist or dermatologist. Plaque psoriasis (PP), prescribed by or in consultation with a dermatologist. UC/ CD, prescribed by or in consultation with a gastroenterologist. HS - dermatologist.UV-ophthalmologist |
| Coverage Duration | Approve through 12/31/23 |
| Other Criteria | RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). JIA/JRA initial. Tried one other systemic therapy for this condition (e.g MTX, sulfasalazine, leflunomide, NSAID) or biologic (eg, etanercept, abatacept, infliximab, anakinra, tocilizumab) or will be starting on adalimumab concurrently with MTX, sulfasalazine, or leflunomide. Approve without trying another agent if pt has absolute contraindication to MTX, sulfasalazine, or leflunomide or if pt has aggressive disease. PP initial-approve if the patient meets one of the |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. CD initial. Tried corticosteroids (CSs) or if CSs are contraindicated or if pt currently on CSs or patient has tried one other conventional systemic therapy for CD (eg, azathioprine, 6-mercaptopurine, MTX, certolizumab, infliximab, ustekinumab, or vedolizumab) OR pt had ileocolonic resection OR enterocutaneous (perianal or abdominal) or rectovaginal fistulas. UC initial. Pt has tried a systemic therapy (eg, 6-mercaptopurine, azathioprine, CSA, tacrolimus, infliximab, golimumab SC, or a corticosteroid such as prednisone or methylprednisolone), or the pt has pouchitis and has tried therapy with an antibiotic, probiotic, corticosteroid enema, or mesalamine (Rowasa) enema. FDA approve indications cont tx - must respond to tx as determined by prescriber. HS - tried ONE other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin). Clinical criteria incorporated into the Humira 40 mg quantity limit edit allow for approval of additional quantities to accommodate induction dosing. The allowable quantity is dependent upon the induction dosing regimen for the applicable FDA-labeled indications as outlined in product labeling.</p> |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

HYDROXYCHLOROQUINE

Products Affected

- hydroxychloroquine oral tablet 200 mg

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

IBRANCE

Products Affected

- Ibrance

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Breast cancer - approve recurrent or metastatic, hormone receptor positive (HR+) [i.e., estrogen receptor positive- (ER+) and/or progesterone receptor positive (PR+)] disease, and HER2-negative breast cancer when the pt meets ONE of the following 1. Pt is postmenopausal and Ibrance will be used in combination with anastrozole, exemestane, or letrozole 2, pt is premenopausal or perimenopausal and is receiving ovarian suppression/ablation with GnRH agonists, or has had surgical bilateral oophorectomy, or ovarian irradiation AND meets one of the following conditions: Ibrance will be used in combination with anastrozole, exemestane, or letrozole or Ibrance will be used in combination with fulvestrant 3. pt is a man (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) who is receiving GnRH analog AND Ibrance with be used in combination with anastrozole, exemestane, or letrozole or Ibrance will be used in combination with fulvestrant 4. Pt is postmenopausal and Ibrance will be used in combination with fulvestrant. Liposarcoma-approve if the patient has well-differentiated/dedifferentiated liposarcoma (WD-DDLS). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Liposarcoma, pre/peri-menopausal women with breast cancer in combination with an aromatase inhibitor |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

ICATIBANT

Products Affected

- icatibant
- Sajazir

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II] - Treatment of Acute Attacks, Initial Therapy-the patient has HAE type I or type II as confirmed by the following diagnostic criteria (i and ii): i. the patient has low levels of functional C1-INH protein (less than 50 percent of normal) at baseline, as defined by the laboratory reference values AND ii. the patient has lower than normal serum C4 levels at baseline, as defined by the laboratory reference values. Patients who have treated previous acute HAE attacks with icatibant-the patient has treated previous acute HAE type I or type II attacks with icatibant AND according to the prescribing physician, the patient has had a favorable clinical response (e.g., decrease in the duration of HAE attacks, quick onset of symptom relief, complete resolution of symptoms, decrease in HAE acute attack frequency or severity) with icatibant treatment. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ICLUSIG

Products Affected

- Iclusig

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, the Philadelphia chromosome (Ph) status of the leukemia must be reported. T315I status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Approve if the patient meets one of the following: 1. Patient has CML or ALL that is Ph+, T315I-positive or, 2. patient has CML, chronic phase with resistance or intolerance to at least two prior TKIs or, 3. patient has accelerated phase or blast phase CML or Philadelphia chromosome positive ALL for whom no other TKIs are indicated. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

IDHIFA

Products Affected

- Idhifa

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | IDH2-mutation status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | AML - approve if the patient is IDH2-mutation status positive as detected by an approved test |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

IMATINIB

Products Affected

- imatinib oral tablet 100 mg, 400 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. |
| Age Restrictions | ASM, DFSP, HES, MDS/MPD/Myeloid/Lymphoid Neoplasms-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | For ALL/CML, must have Ph-positive for approval of imatinib. Kaposi's Sarcoma-approve if the patient has tried at least one regimen AND has relapsed or refractory disease. Pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)-patient has tried Turalio or according to the prescriber, the patient cannot take Turalio. Myelodysplastic/myeloproliferative disease-approve if the condition is associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.Graft versus host disease, chronic-approve if the patient has tried at least one conventional systemic treatment (e.g., imbruvica). Metastatic melanoma-approve if the patient has c-Kit-positive advanced/recurrent or metastatic melanoma. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement or an FIP1L1-PDGFR or PDGFRB rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Chordoma, advanced, aggressive or unresectable fibromatosis (desmoid tumors), cKit positive advanced/recurrent or metastatic melanoma, Kaposi's Sarcoma and pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor, myeloid/lymphoid neoplasms with eosinophilia. |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

IMBRUVICA

Products Affected

- Imbruvica oral capsule 140 mg, 70 mg
- Imbruvica oral suspension
- Imbruvica oral tablet

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | GVHD-1 year, all others-3 years |
| Other Criteria | Marginal Zone Lymphoma - Approve. GVHD-Approve if the patient has tried one conventional systemic treatment for graft versus host disease (e.g., corticosteroids [methylprednisolone, prednisone], cyclosporine, tacrolimus, mycophenolate mofetil, imatinib, Jakafi). B-cell lymphoma-approve if the patient is using Imbruvica as second-line or subsequent therapy according to the prescribing physician. Central nervous system Lymphoma (primary)/Hairy Cell Leukemia-approve if relapsed or refractory. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Central Nervous System Lymphoma (Primary), Hairy Cell Leukemia, B-Cell Lymphoma (e.g., gastric MALT lymphoma, nongastric MALT lymphoma, AIDS related, post-transplant lymphoproliferative disorder). |
| Part B Prerequisite | No |

INJECTABLE TESTOSTERONE PRODUCTS

Products Affected

- testosterone cypionate
- testosterone enanthate

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, lab results |
| Age Restrictions | Delayed puberty or induction of puberty in males-14 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Delayed puberty or induction of puberty in males-6 months, all others-12 months |
| Other Criteria | Hypogonadism (primary or secondary) in males - initial therapy, approve if all of the following criteria are met: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) [eg, depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido, AND 2) patient has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. Hypogonadism (primary or secondary) in males - continuing therapy, approve if the patient meets all of the following criteria: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) AND 2) patient had at least one pre-treatment serum testosterone level that was low. Delayed puberty or induction of puberty in males - Approve testosterone enanthate. Breast cancer in females-approve testosterone enanthate. Male is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression. Female is defined as an individual with the biological traits of a woman, regardless of the individual's gender identity or gender expression |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

INLYTA

Products Affected

- Inlyta oral tablet 1 mg, 5 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Advanced Renal cell carcinoma-approve. Differentiated thyroid cancer, approve if patient is refractory to radioactive iodine therapy. Soft tissue sarcoma-approve if the patient has alveolar soft part sarcoma and the medication will be used in combination with Keytruda (pembrolizumab). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Differentiated (i.e., papillary, follicular, and Hurthle) Thyroid Carcinoma, Soft tissue sarcoma |
| Part B Prerequisite | No |

INQOVI

Products Affected

- Inqovi

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

INREBIC

Products Affected

- Inrebic

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Myelofibrosis (MF), including Primary MF, Post-Polycythemia Vera MF, and Post-Essential Thrombocythemia MF-approve if the patient has intermediate-2 or high-risk disease. Myeloid/Lymphoid Neoplasms with Eosinophilia-approve if the tumor has a JAK2 rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Myeloid/Lymphoid Neoplasms with Eosinophilia |
| Part B Prerequisite | No |

IRESSA

Products Affected

- Iressa

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | NSCLC-approve if the patient has advanced or metastatic disease and the patient has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: Examples of sensitizing EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

IVERMECTIN (ORAL)

Products Affected

- ivermectin oral

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 30 days |
| Other Criteria | Pediculosis-approve if the patient has infection caused by pediculus humanus capitis (head lice), pediculus humanus corporis (body lice), or has pediculosis pubis caused by phthirus pubis (pubic lice). Scabies-approve if the patient has classic scabies, treatment resistant scabies, is unable to tolerate topical treatment, has crusted scabies or is using ivermectin tablets for prevention and/or control of scabies. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Ascariasis, Enterobiasis (pinworm infection), Hookworm-related cutaneous larva migrans, Mansonella ozzardi infection, Mansonella streptocerca infection, Pediculosis, Scabies. Trichuriasis, Wucheria bancrofti infection |
| Part B Prerequisite | No |

IVIG

Products Affected

- Privigen

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | Part B versus D determination per CMS guidance to establish if drug used for PID in pt's home. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

JAKAFI

Products Affected

- Jakafi

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | ALL-less than 21 years of age, GVHD-12 and older, MF/PV/CMML-2/essential thrombo/myeloid/lymphoid neoplasm-18 and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | GVHD-1 year, all others-Authorization will be for 3 years. |
| Other Criteria | For polycythemia vera patients must have tried hydroxyurea. ALL-approve if the mutation/pathway is Janus associated kinase (JAK)-related. GVHD, chronic-approve if the patient has tried one conventional systemic treatment for graft versus host disease. GVHD, acute-approve if the patient has tried one systemic corticosteroid. GVHD, acute-approve if the patient has tried one systemic corticosteroid. Polycythemia vera-approve if the patient has tried hydroxyurea. Atypical chronic myeloid leukemia-approve if the patient has a CSF3R mutation or a janus associated kinase mutation 2 (JAK2). Chronic monomyelocytic leukemia-2 (CMML-2)-approve if the patient is also receiving a hypomethylating agent. Essential thrombocythemia-approve if the patient has tried hydroxyurea, peginterferon alfa-2a or anagrelide. Myeloid/lymphoid neoplasms-approve if the patient has eosinophilia and the tumor has a janus associated kinase 2 (JAK2) rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Acute lymphoblastic leukemia, atypical chronic myeloid leukemia, chronic monomyelocytic leukemia-2 (CMML-2), essential thrombocythemia, myeloid/lymphoid neoplasms |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

KALYDECO

Products Affected

- Kalydeco oral granules in packet
- Kalydeco oral tablet

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | Combination use with Orkambi, Trikafta or Symdeko |
| Required Medical Information | N/A |
| Age Restrictions | 4 months of age and older |
| Prescriber Restrictions | prescribed by or in consultation with a pulmonologist or a physician who specializes in CF |
| Coverage Duration | 1 year |
| Other Criteria | CF - must have one mutation in the CFTR gene that is responsive to the requested medication. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

KERENDIA

Products Affected

- Kerendia

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Concomitant use with spironolactone or eplerenone |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older (initial and continuation therapy) |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | <p>Diabetic kidney disease, initial-approve if the patient meets the following criteria (i, ii and iii): i. Patient has a diagnosis of type 2 diabetes, AND ii. Patient meets one of the following (a or b): a)Patient is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) OR b)According to the prescriber, patient has a contraindication to ACE inhibitor or ARB therapy, AND iii. At baseline (prior to the initiation of Kerendia), patient meets all of the following (a, b, and c): a)Estimated glomerular filtration rate greater than or equal to 25 mL/min/1.73 m² AND b)Urine albumin-to-creatinine ratio greater than or equal to 30 mg/g AND c)Serum potassium level less than or equal to 5.0 mEq/L. Diabetic kidney disease, continuation-approve if the patient meets the following criteria (i and ii): i. Patient has a diagnosis of type 2 diabetes, AND ii. Patient meets one of the following (a or b): a. Patient is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) OR b. According to the prescriber, patient has a contraindication to ACE inhibitor or ARB therapy.</p> |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

KISQALI

Products Affected

- Kisqali Femara Co-Pack oral tablet 200 mg/day(200 mg x 1)-2.5 mg, 400 mg/day(200 mg x 2)-2.5 mg, 600 mg/day(200 mg x 3)-2.5 mg
- Kisqali oral tablet 200 mg/day (200 mg x 1), 400 mg/day (200 mg x 2), 600 mg/day (200 mg x 3)

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Breast cancer - approve recurrent or metastatic hormone receptor positive (HR+) [i.e., estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)]disease, and HER2-negative breast cancer when the pt meets ONE of the following 1. Pt is postmenopausal and Kisqali will be used in combination with anastrozole, exemestane, or letrozole 2. pt is premenopausal or perimenopausal and is receiving ovarian suppression/ablation with GnRH agonist, or has had surgical bilateral oophorectomy, or ovarian irradiation AND Kisqali will be used in combination with anastrozole, exemestane, or letrozole 3. pt is a man (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) who is receiving GnRH analog AND Kisqali with be used in combination with anastrozole, exemestane or letrozole. 4. Patient is postmenopausal, pre/perimenopausal (patient receiving ovarian suppression/ablation with a GnRH agonist or has had surgical bilateral oophorectomy or ovarian irradiation) or a man, and Kisqali (not Co-Pack) will be used in combination with fulvestrant. If the request is for Kisqali Femara, patients do not need to use in combination with anastrozole, exemestane or letrozole. Patients must have a trial of Ibrance or Verzenio prior to approval of Kisqali/Kisqali Femara Co-Pack unless the patient meets one |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | of the following-a) Patient has been taking Kisqali or Kisqali Femara Co-Pack and is continuing therapy OR b) Patient is pre/perimenopausal and will be using Kisqali or Kisqali Femara Co-Pack in combination with an aromatase inhibitor as initial endocrine-based therapy OR c) Kisqali will be used in combination with fulvestrant in postmenopausal female or male patients as initial endocrine-based therapy |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

KORLYM

Products Affected

- Korlym

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior surgeries |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of Cushing's syndrome. |
| Coverage Duration | Endogenous Cushing's Synd-1 yr. Pt awaiting surgery or response after radiotherapy-4 months |
| Other Criteria | Endogenous Cushing's Syndrome-Approve if, according to the prescribing physician, the patient is not a candidate for surgery or surgery has not been curative AND if Korlym is being used to control hyperglycemia secondary to hypercortisolism in patients who have type 2 diabetes mellitus or glucose intolerance. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Endogenous Cushing's Syndrome, awaiting surgery. Patients with Endogenous Cushing's syndrome, awaiting a response after radiotherapy |
| Part B Prerequisite | No |

KYNMOBI

Products Affected

- Kynmobi sublingual film 10 mg, 15 mg, 20 mg, 25 mg, 30 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Concurrent Use with a Serotonin 5-HT3 Antagonist |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | Parkinson's Disease-Approve if the patient is experiencing off episodes, such as muscle stiffness, slow movements or difficulty starting movements, is currently receiving carbidopa/levodopa and has previously tried one other treatment for off episodes and experienced intolerance or inadequate efficacy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

LAPATINIB

Products Affected

- lapatinib

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which lapatinib is being used. Metastatic breast cancer, HER2 status or hormone receptor (HR) status. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | HER2-positive recurrent or metastatic breast cancer, approve if lapatinib will be used in combination with capecitabine OR trastuzumab and the patient has tried at least two prior anti-HER2 based regimens OR the medication will be used in combination with an aromatase inhibitor and and the patient has HR+ disease and the patient is a postmenopausal woman or the patient is premenopausal or perimenopausal woman and is receiving ovarian suppression/ablation with a GnRH agonist, surgical bilateral oophorectomy or ovarian irradiation OR the patient is a man and is receiving a GnRH analog. Colon or rectal cancer-approve if the patient has unresectable advanced or metastatic disease that is human epidermal receptor 2 (HER2) amplified and with wild-type RAS and BRAF disease and the patient has tried at least one chemotherapy regimen or is not a candidate for intensive therapy and the medication is used in combination with trastuzumab (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan) and the patient has not been previously treated with a HER2-inhibitor. Bone Cancer-approve if the patient has recurrent chordoma and if the patient has epidermal growth-factor receptor (EGFR)-positive disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Bone cancer-chordoma, colon or rectal cancer |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

LENVIMA

Products Affected

- Lenvima

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | DTC - must be refractory to radioactive iodine treatment for approval. RCC, advanced disease- approve if the pt meets i or ii: i. Lenvima is being used in combination with pembrolizumab OR ii. Lenvima is used in combination with everolimus and the patient meets a or b - a. Patient has clear cell histology and patient has tried one antiangiogenic therapy or b. patient has non-clear cell histology. MTC-approve if the patient has tried Caprelsa or Cometriq. Endometrial Carcinoma-Approve if the patient meets the following criteria (A, B, C, and D): A) The patient has advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) AND B) The medication is used in combination with Keytruda (pembrolizumab for intravenous injection) AND C)the disease has progressed on at least one prior systemic therapy AND D) The patient is not a candidate for curative surgery or radiation. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Medullary Thyroid Carcinoma (MTC) and renal cell carcinoma with non-clear cell histology |
| Part B Prerequisite | No |

LIDOCAINE PATCH

Products Affected

- lidocaine topical adhesive patch,medicated
5 %

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Diabetic neuropathic pain, chronic back pain |
| Part B Prerequisite | No |

LONG ACTING OPIOIDS

Products Affected

- hydromorphone oral tablet extended release 24 hr
- methadone oral solution 10 mg/5 mL, 5 mg/5 mL
- methadone oral tablet 10 mg, 5 mg
- morphine oral tablet extended release

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Acute (ie, non-chronic) pain |
| Required Medical Information | Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been tried and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 5) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, in hospice, sickle cell disease or who reside in a long term care facility are not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

LONSURF

Products Affected

- Lonsurf

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Gastric or Gastroesophageal Junction Adenocarcinoma-approve if the patient has been previously treated with at least two chemotherapy regimens for gastric or gastroesophageal junction adenocarcinoma. Colon and rectal cancer-approve per labeling if the patient has been previously treated with a fluopyrimidine, oxaliplatin and irinotecan. If the patient's tumor or metastases are wild-type RAS (KRAS wild type and NRAS wild type) they must also try Erbitux or Vectibix. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

LORBRENA

Products Affected

- Lorbrena oral tablet 100 mg, 25 mg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, ALK status, ROS1 status, previous therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Erdheim Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory myofibroblastic tumor (IMT)-approve if the patient has IMT with ALK translocation. NSCLC - Approve if the patient has ALK-positive metastatic NSCLC, as detected by an approved test. NSCLC-ROS1 Rearrangement-Positive, metastatic NSCLC-approve if the patient has tried at least one of crizotinib, entrectinib or ceritinib. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Non-small cell lung cancer (NSCLC)-ROS1 Rearrangement-Positive, Erdheim Chester Disease, Inflammatory Myofibroblastic Tumor (IMT) |
| Part B Prerequisite | No |

LOTRONEX

Products Affected

- alosetron

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

LUMAKRAS

Products Affected

- Lumakras

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years |
| Other Criteria | Non-Small Cell Lung Cancer (NSCLC)-approve if the patient has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test AND has been previously treated with at least one systemic regimen. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

LYNPARZA

Products Affected

- Lynparza

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | <p>Ovarian Cancer - Treatment-initial-Approve if the patient meets the following criteria (i and ii): i. The patient has a germline BRCA-mutation as confirmed by an approved test AND has progressed on two or more prior lines of chemotherapy. Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Maintenance monotherapy-Approve if the patient meets one of the following criteria (A or B): A) The patient meets both of the following criteria for first-line maintenance therapy (i and ii): i. The patient has a germline or somatic BRCA mutation-positive disease as confirmed by an approved test AND ii. The patient is in complete or partial response to first-line platinum-based chemotherapy regimen (e.g., carboplatin with paclitaxel, carboplatin with doxorubicin, docetaxel with carboplatin) OR B) The patient is in complete or partial response after at least two platinum-based chemotherapy regimens (e.g., carboplatin with gemcitabine, carboplatin with paclitaxel, cisplatin with gemcitabine).</p> <p>Ovarian, fallopian tube, or primary peritoneal cancer-maintenance, combination therapy-approve if the medication is used in combination with bevacizumab, the patient has homologous recombination deficiency (HRD)-positive disease, as confirmed by an approved test and the patient is in complete or partial response to first-line platinum-based chemotherapy regimen. Breast cancer, adjuvant-approve if the patient has germline BRCA mutation-positive, HER2-negative breast cancer and the patient has hormone receptor positive disease and did not have a pathologic complete</p> |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>response to neoadjuvant therapy or the patient has node positive disease after receiving adjuvant therapy. If the patient has hormone receptor negative disease, approve if the patient has tried neoadjuvant or adjuvant therapy and has residual disease. Breast cancer, recurrent or metastatic disease-approve if the patient has recurrent or metastatic disease, has germline BRCA mutation-positive breast cancer and the patient has HER2-negative breast cancer. Pancreatic Cancer-maintenance therapy-approve if the patient has a germline BRCA mutation-positive metastatic disease and the disease has not progressed on at least 16 weeks of treatment with a first-line platinum-based chemotherapy regimen. Prostate cancer-castration resistant-approve if the patient has metastatic disease, the medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog or the patient has had a bilateral orchiectomy, the patient has germline or somatic homologous recombination repair (HRR) gene-mutated disease, as confirmed by an approved test, the patient does not have a PPP2R2A mutation and the patient has been previously treated with at least one androgen receptor directed therapy. Uterine Leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Uterine Leiomyosarcoma |
| Part B Prerequisite | No |

MEGACE

Products Affected

- megestrol oral suspension 400 mg/10 mL (40 mg/mL), 625 mg/5 mL (125 mg/mL)
- megestrol oral tablet

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | Coverage is not provided for weight gain for cosmetic reasons. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

MEKINIST

Products Affected

- Mekinist oral tablet 0.5 mg, 2 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Mekinist is being used. For melanoma, thyroid cancer and NSCLC must have documentation of BRAF V600 mutations |
| Age Restrictions | 6 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Melanoma must be used in patients with BRAF V600 mutation, and patient has unresectable, advanced (including Stage III or Stage IV disease), or metastatic melanoma. Note-This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery. For NSCLC requires BRAF V600E Mutation and use in combination with Tafenlar. Thyroid cancer, anaplastic-patient has locally advanced or metastatic anaplastic disease AND Mekinist will be taken in combination with Tafenlar, unless intolerant AND the patient has BRAF V600-positive disease. Ovarian/fallopian tube/primary peritoneal cancer-approve if the patient has recurrent disease and the medication is used for low-grade serous carcinoma. Biliary Tract Cancer-approve if the patient has tried at least one systemic chemotherapy regimen, patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Tafenlar. Central Nervous System Cancer-approve if the medication is being used for one of the following situations (i, ii, or iii): i) adjuvant treatment of one of the following conditions: pilocytic astrocytoma or pleomorphic xanthoastrocytoma or ganglioglioma, OR ii) recurrent disease for one of the following conditions: low-grade glioma OR anaplastic glioma OR glioblastoma, OR iii) melanoma with brain metastases AND patient has BRAF V600 mutation-positive disease AND medication will be taken in combination with Tafenlar (dabrafenib). Histiocytic neoplasm-approve if patient has Langerhans cell histiocytosis and one of the |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | following: multisystem disease or pulmonary disease or central nervous system lesions or patient has Erdheim Chester disease or Rosai-Dorfman disease AND patient has BRAF V600-mutation positive disease. Metastatic or Solid Tumors-Approve if the patient meets the following (A, B, and C): A) Patient has BRAF V600 mutation-positive disease, AND B) The medication will be taken in combination with Tafenlar (dabrafenib capsules), AND C) Patient has no satisfactory alternative treatment options. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Ovarian/Fallopian Tube/Primary Peritoneal Cancer, Biliary Tract Cancer, Central Nervous System Cancer, Histiocytic Neoplasm. |
| Part B Prerequisite | No |

MEKTOVI

Products Affected

- Mektovi

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, BRAF V600 status, concomitant medications |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Melanoma - approve if the patient has unresectable, advanced or metastatic melanoma AND has a BRAF V600 mutation AND Mektovi will be used in combination with Braftovi. Histiocytic neoplasm-approve if the patient has Langerhans cell histiocytosis and one of the following (i, ii, or iii): i. multisystem disease OR, ii. pulmonary disease or, iii. central nervous system lesions. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Histiocytic Neoplasms |
| Part B Prerequisite | No |

MEMANTINE

Products Affected

- memantine oral capsule, sprinkle, ER 24hr
- memantine oral solution
- memantine oral tablet
- Namzaric

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Indication for which memantine is being prescribed. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with mild to moderate vascular dementia. |
| Part B Prerequisite | No |

MODAFINIL/ARMODAFINIL

Products Affected

- armodafinil
- modafinil oral tablet 100 mg, 200 mg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Excessive daytime sleepiness associated with narcolepsy-prescribed by or in consultation with a sleep specialist physician or neurologist |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | Excessive sleepiness associated with Shift Work Sleep Disorder (SWSD) - approve if patient is working at least 5 overnight shifts per month. Adjunctive/augmentation treatment for depression in adults if the patient is concurrently receiving other medication therapy for depression. Excessive daytime sleepiness associated with obstructive sleep apnea/hypoapnea syndrome-approve. Excessive daytime sleepiness associated with Narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Excessive daytime sleepiness (EDS) associated with myotonic dystrophy (modafinil only). Adjunctive/augmentation for treatment of depression in adults (modafinil only). |
| Part B Prerequisite | No |

MYALEPT

Products Affected

- Myalept

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by, or in consultation with, an endocrinologist or a geneticist physician specialist |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NATPARA

Products Affected

- Natpara

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist. |
| Coverage Duration | 1 year |
| Other Criteria | Chronic hypoparathyroidism, initial therapy - approve if before starting Natpara, serum calcium concentration is greater than 7.5 mg/dL and 25-hydroxyvitamin D stores are sufficient per the prescribing physician. Chronic hypoparathyroidism, continuing therapy - approve if during Natpara therapy, the patient's 25-hydroxyvitamin D stores are sufficient per the prescribing physician, AND the patient is responding to Natpara therapy, as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NAYZILAM

Products Affected

- Nayzilam

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, other medications used at the same time |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiepileptic medication(s). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NERLYNX

Products Affected

- Nerlynx

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Stage of cancer, HER2 status, previous or current medications tried |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Adjuvant tx-Approve for 1 year (total), advanced or metastatic disease-3yrs |
| Other Criteria | Breast cancer adjuvant therapy - approve if the patient meets all of the following criteria: patient will not be using this medication in combination with HER2 antagonists, Patient has HER2-positive breast cancer AND patient has completed one year of adjuvant therapy with trastuzumab OR could not tolerate one year of therapy. Breast cancer, recurrent or metastatic disease-approve if the patient has HER-2 positive breast cancer, Nerlynx will be used in combination with capecitabine and the patient has tried at least two prior anti-HER2 based regimens. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NEXAVAR

Products Affected

- sorafenib

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Osteosarcoma, approve if the patient has tried standard chemotherapy and have relapsed/refractory or metastatic disease. GIST, approve if the patient has tried TWO of the following: Gleevec (imatinib mesylate), Ayvakit (avapritinib), Sutent (sunitinib), Sprycel (dasatinib), Qinlock (ripretinib) or Stivarga (regorafenib). Differentiated (ie, papillary, follicular, Hurthle) thyroid carcinoma (DTC), approve if the patient is refractory to radioactive iodine treatment. Medullary thyroid carcinoma, approve if the patient has tried Caprelsa (vandetanib) or Cometriq (cabozantinib). AML - Approve if disease is FLT3-ITD mutation positive as detected by an approved test. Renal cell carcinoma (RCC)-approve if the patient has relapsed or Stage IV clear cell histology and the patient has tried at least one prior systemic therapy (e.g., Inlyta, Votrient, Sutent Cabometyx). Ovarian, fallopian tube, primary peritoneal cancer-approve if the patient has platinum resistant disease and Nexavar (sorafenib) is used in combination with topotecan. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Osteosarcoma, angiosarcoma, desmoids tumors (aggressive fibromatosis), gastrointestinal stromal tumors (GIST), medullary thyroid carcinoma, Acute Myeloid Leukemia, Chordoma with recurrent disease, solitary fibrous tumor and hemangiopericytoma, ovarian, fallopian tube, primary peritoneal cancer |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

NILUTAMIDE

Products Affected

- nilutamide

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Prostate cancer-approve if nilutamide is used concurrently with a luteinizing hormone-releasing hormone (LHRH) agonist. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NINLARO

Products Affected

- Ninlaro

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | MM - be used in combination with Revlimid and dexamethasone OR pt had received at least ONE previous therapy for multiple myeloma OR the agent will be used following autologous stem cell transplantation (ASCT). Systemic light chain amyloidosis-approve if the patient has tried at least one other regimen for this condition. Waldenstrom Macroglobulinemia/lymphoplasmacytic lymphoma-approve if used in combination with a rituximab product and dexamethasone (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with systemic light chain amyloidosis, Waldenstrom Macroglobulinemia/lymphoplasmacytic lymphoma |
| Part B Prerequisite | No |

NITISINONE

Products Affected

- nitisinone

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use of therapy with nitisinone products |
| Required Medical Information | Diagnosis, genetic tests and lab results (as specified in the Other Criteria field) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases) |
| Coverage Duration | 1 year |
| Other Criteria | Hereditary Tyrosinemia, Type 1-approve if the prescriber confirms the diagnosis was confirmed by genetic testing confirming a mutation of the FAH gene OR elevated serum levels of alpha-fetoprotein (AFP) and succinylacetone. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NIVESTYM

Products Affected

- Nivestym

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Cancer/AML, MDS, ALL, oncologist or a hematologist. Cancer patients receiving BMT and PBPC, prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. Radiation-expertise in acute radiation. SCN, AA - hematologist. HIV/AIDS neutropenia, infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS. |
| Coverage Duration | chemo/SCN/AML-6mo.HIV/AIDS-4mo.MDS-3mo.PBPC,Drug induce A/N,AA,ALL,BMT-3mo. Radi-1mo, Other=12mo. |
| Other Criteria | Cancer patients receiving chemotherapy, approve if the patient meets one of the following conditions: patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20 percent based on the chemotherapy regimen), patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20 percent based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status, or HIV infection), patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor (eg, Leukine, filgrastim products, pegfilgrastim products) and a reduced dose or frequency of chemotherapy may compromise treatment, patient has received chemotherapy has febrile neutropenia and has at least one risk factor (eg, sepsis syndrome, aged greater than 65 years, severe neutropenia |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | [absolute neutrophil account less than 100 cells/mm ³], neutropenia expected to be greater than 10 days in duration, invasive fungal infection). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Neutropenia associated with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). Treatment of myelodysplastic syndromes (MDS). Drug induced agranulocytosis or neutropenia. Aplastic anemia (AA). Acute lymphocytic leukemia (ALL). Radiation Syndrome (Hematopoietic Syndrome of Acute Radiation Syndrome). |
| Part B Prerequisite | No |

NON-INJECTABLE TESTOSTERONE PRODUCTS

Products Affected

- testosterone transdermal gel in metered-dose pump 10 mg/0.5 gram /actuation, 20.25 mg/1.25 gram (1.62 %) 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram)
- testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram), testosterone transdermal solution in metered pump w/app

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis of primary hypogonadism (congenital or acquired) in males. Diagnosis of secondary (hypogonadotropic) hypogonadism (congenital or acquired) in males. Hypogonadism (primary or secondary) in males, serum testosterone level. [Man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.] |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | Hypogonadism (primary or secondary) in males - initial therapy, approve if all of the following criteria are met: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) [eg, depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido, AND 2) patient has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. Hypogonadism (primary or secondary) in males - continuing therapy, approve if the patient meets all of the following criteria: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) AND 2) patient had at least one pre-treatment serum testosterone level that was low. [Note: male is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.] |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|--------------------------------|-------------------------|
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NORTHERA

Products Affected

- droxidopa

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Medication history |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with a cardiologist or a neurologist |
| Coverage Duration | 12 months |
| Other Criteria | NOH, approve if the patient meets ALL of the following criteria: a) Patient has been diagnosed with symptomatic NOH due to primary autonomic failure (Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy, AND b) Patient has tried midodrine |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NUBEQA

Products Affected

- Nubeqa

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Prostate cancer - non-metastatic, castration resistant-approve if the requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog or if the patient has had a bilateral orchiectomy. Prostate cancer-metastatic, castration sensitive-approve if the medication is used in combination with docetaxel and the medication will be used in combination with a GnRH agonist or in combination with Firmagon or if the patient had a bilateral orchiectomy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NUEDEXTA

Products Affected

- Nuedexta

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NUPLAZID

Products Affected

- Nuplazid

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NURTEC

Products Affected

- Nurtec ODT

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Migraine, Acute treatment-approve. Preventive treatment of episodic migraine-approve if the patient has greater than or equal to 4 but less than 15 migraine headache days per month (prior to initiating a migraine preventive medication and has tried at least two standard prophylactic pharmacologic therapies, at least one drug each from a different pharmacologic class (e.g., anticonvulsant, beta-blocker), and has had inadequate responses to those therapies or the patient has a contraindication to other prophylactic pharmacologic therapies according to the prescribing physician. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

NYVEPRIA

Products Affected

- Nyvepria

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Cancer patients receiving chemotherapy, if prescribed by or in consultation with an oncologist or hematologist. PBPC-prescribed by or in consultation with an oncologist, hematologist, or physician that specializes in transplantation |
| Coverage Duration | Cancer pts receiving chemo-6 mo. PBPC-1 mo |
| Other Criteria | Cancer patients receiving chemotherapy, approve if - the patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20 percent based on the chemotherapy regimen), OR the patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20 percent based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia according to the prescribing physician (eg, aged greater than or equal to 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status or HIV infection, OR the patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients undergoing PBPC collection and therapy |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

OCALIVA

Products Affected

- Ocaliva

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Patient does not have cirrhosis or has compensated cirrhosis without evidence of portal hypertension |
| Required Medical Information | Prescriber specialty, lab values, prior medications used for diagnosis and length of trials |
| Age Restrictions | 18 years and older (initial) |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician (initial) |
| Coverage Duration | 6 months initial, 1 year cont. |
| Other Criteria | Initial treatment of PBC-Patient must meet both 1 and 2-1. Patient has a diagnosis of PBC as defined by TWO of the following:a)Alkaline phosphatase (ALP) elevated above the upper limit of normal as defined by normal laboratory reference values b)Positive anti-mitochondrial antibodies (AMAs) or other PBC-specific auto-antibodies, including sp100 or gp210, if AMA is negative c)Histologic evidence of primary biliary cholangitis (PBC) from a liver biopsy 2. Patient meets ONE of the following: a) Patient has been receiving ursodiol therapy for greater than or equal to 1 year and has had an inadequate response. b) Patient is unable to tolerate ursodiol therapy. Cont tx - approve if the patient has responded to Ocaliva therapy as determined by the prescribing physician (e.g., improved biochemical markers of PBC (e.g., alkaline phosphatase [ALP], bilirubin, gamma-glutamyl transpeptidase [GGT], aspartate aminotransferase [AST], alanine aminotransferase [ALT] levels)). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OCTREOTIDE INJECTABLE

Products Affected

- octreotide acetate injection solution

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Acromegaly-prescr/consult w/endocrinologist. NETs-prescr/consult w/oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescr/consult w/endo/onc/neuro.Meningioma-prescr/consult w/oncologist, radiologist, neurosurg/thymoma/thymic carcinoma-presc/consult with oncologist |
| Coverage Duration | 1 year |
| Other Criteria | Acromegaly-approve if patient meets ONE of the following (i, ii, or iii): i. Patient has had an inadequate response to surgery and/or radiotherapy OR ii. Patient is NOT an appropriate candidate for surgery and/or radiotherapy OR iii. Patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) AND Patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Meningioma, thymoma and thymic carcinoma, pheochromocytoma and paraganglioma |
| Part B Prerequisite | No |

ODOMZO

Products Affected

- Odomzo

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | BCC - Must not have had disease progression while on Erivedge (vismodegib). |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Locally advanced BCC approve if the BCC has recurred following surgery/radiation therapy or if the patient is not a candidate for surgery AND the patient is not a candidate for radiation therapy, according to the prescribing physician. Metastatic BCC - approve. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Metastatic BCC |
| Part B Prerequisite | No |

OFEV

Products Affected

- Ofev

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years of age and older |
| Prescriber Restrictions | IPF-Prescribed by or in consultation with a pulmonologist. Interstitial lung disease associated with systemic sclerosis-prescribed by or in consultation with a pulmonologist or rheumatologist. |
| Coverage Duration | 1 year |
| Other Criteria | IPF - must have FVC greater than or equal to 40 percent of the predicted value AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP. Interstitial lung disease associated with systemic sclerosis-approve if the FVC is greater than or equal to 40 percent of the predicted value and the diagnosis is confirmed by high-resolution computed tomography. Chronic fibrosing interstitial lung disease-approve if the forced vital capacity is greater than or equal to 45 percent of the predicted value AND according to the prescriber the patient has fibrosing lung disease impacting more than 10 percent of lung volume on high-resolution computed tomography AND according to the prescriber the patient has clinical signs of progression. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ONUREG

Products Affected

- Onureg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | AML - Approve if the patient meets the following criteria (both A and B): A) Following intensive induction chemotherapy, the patient achieves one of the following according to the prescriber (i or ii): i. First complete remission OR ii. First complete remission with incomplete blood count recovery AND B) Patient is not able to complete intensive curative therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ORENITRAM

Products Affected

- Orenitram

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, results of right heart cath |
| Age Restrictions | N/A |
| Prescriber Restrictions | PAH must be prescribed by or in consultation with a cardiologist or a pulmonologist. |
| Coverage Duration | 3 years |
| Other Criteria | For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ORGOVYX

Products Affected

- Orgovyx

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Prostate Cancer-approve |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ORKAMBI

Products Affected

- Orkambi oral granules in packet
- Orkambi oral tablet

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | Combination use with Kalydeco, Trikafta or Symdeko. |
| Required Medical Information | N/A |
| Age Restrictions | 1 year of age and older |
| Prescriber Restrictions | prescribed by or in consultation with a pulmonologist or a physician who specializes in CF |
| Coverage Duration | 3 years |
| Other Criteria | CF - homozygous for the Phe508del (F508del) mutation in the CFTR gene (meaning the patient has two copies of the Phe508del mutation) |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

OXERVATE

Products Affected

- Oxervate

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Treatment duration greater than 16 weeks per affected eye(s) |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by an ophthalmologist or an optometrist |
| Coverage Duration | Initial-8 weeks, continuation-approve for an additional 8 weeks |
| Other Criteria | Patients who have already received Oxervate-approve if the patient has previously received less than or equal to 8 weeks of treatment per affected eye(s) and the patient has a recurrence of neurotrophic keratitis. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PANRETIN

Products Affected

- Panretin

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a dermatologist, oncologist, or infectious disease specialist |
| Coverage Duration | 1 year |
| Other Criteria | Kaposi Sarcoma-approve if the patient is not receiving systemic therapy for Kaposi Sarcoma. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PEMAZYRE

Products Affected

- Pemazyre

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years |
| Other Criteria | Cholangiocarcinoma-approve if the patient has unresectable locally advanced or metastatic disease and the tumor has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an approved test AND the patient has been previously treated with at least one systemic therapy regimen. Myeloid/lymphoid neoplasms-approve if the patient has eosinophilia and the cancer has fibroblast growth factor receptor 1 (FGFR1) rearrangement, as detected by an approved test and the cancer is in chronic phase or blast phase. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PENICILLAMINE

Products Affected

- penicillamine oral tablet

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Wilson's Disease-Prescribed by or in consultation with a gastroenterologist, hepatologist or liver transplant physician |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PHENYLBUTYRATE

Products Affected

- sodium phenylbutyrate

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Concomitant use of Ravicti and Buphenyl |
| Required Medical Information | Diagnosis, genetic tests and lab results (as specified in the Other Criteria field) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases) |
| Coverage Duration | Pt meets criteria with no genetic test - 3 mo approval. Pt had genetic test - 12 mo approval |
| Other Criteria | Urea cycle disorders-approve if genetic testing confirmed a mutation resulting in a urea cycle disorder or if the patient has hyperammonemia. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PHEOCHROMOCYTOMA

Products Affected

- metyrosine

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior medication trials |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist or a physician who specializes in the management of pheochromocytoma (initial and continuation therapy for metyrosine) |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | If the requested drug is metyrosine for initial therapy, approve if the patient has tried a selective alpha blocker (e.g., doxazosin, terazosin or prazosin). If the requested drug is metyrosine for continuation therapy, approve if the patient is currently receiving metyrosine or has received metyrosine in the past. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PHOSPHODIESTERASE-5 INHIBITORS FOR PAH

Products Affected

- sildenafil (Pulmonary Arterial Hypertension) oral tablet

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, right heart cath results |
| Age Restrictions | N/A |
| Prescriber Restrictions | For PAH, if prescribed by, or in consultation with, a cardiologist or a pulmonologist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment. Clinical criteria incorporated into the quantity limit edits for sildenafil 20 mg tablets require confirmation that the indication is PAH (ie, FDA labeled use) prior to reviewing for quantity exception. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PIQRAY

Products Affected

- Piqray

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapies |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Breast Cancer. Approve if the patient meets the following criteria (A, B, C, D, E and F): A) The patient is a postmenopausal female or a male or premenopausal and is receiving ovarian suppression with a gonadotropin-releasing hormone (GnRH) analog or has had surgical bilateral oophorectomy or ovarian irradiation AND B) The patient has advanced or metastatic hormone receptor (HR)-positive disease AND C) The patient has human epidermal growth factor receptor 2 (HER2)-negative disease AND D) The patient has PIK3CA-mutated breast cancer as detected by an approved test AND E) The patient has progressed on or after at least one prior endocrine-based regimen (e.g., anastrozole, letrozole, exemestane, tamoxifen, toremifene) AND F) Piqray will be used in combination with fulvestrant injection. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Treatment of breast cancer in premenopausal women |
| Part B Prerequisite | No |

POMALYST

Products Affected

- Pomalyst

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Kaposi Sarcoma/MM-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years |
| Other Criteria | Kaposi Sarcoma-Approve if the patient meets one of the following (i or ii): i. patient is Human Immunodeficiency Virus (HIV)-negative OR ii. patient meets both of the following (a and b): a) The patient is Human Immunodeficiency Virus (HIV)-positive AND b) The patient continues to receive highly active antiretroviral therapy (HAART). CNS Lymphoma-approve if the patient has relapsed or refractory disease. MM-approve if the patient has received at least one other Revlimid (lenalidomide tablets)-containing regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Systemic Light Chain Amyloidosis, Central Nervous System (CNS) Lymphoma |
| Part B Prerequisite | No |

POSACONAZOLE (ORAL)

Products Affected

- posaconazole

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Aspergillus/Candida prophylaxis, mucormycosis-6 mo, all others-3 months |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | mucormycosis - maintenance, fusariosis, invasive - treatment fungal infections (systemic) in patients with human immunodeficiency virus (HIV) infections (e.g., histoplasmosis, coccidioidomycosis) - treatment. |
| Part B Prerequisite | No |

PROLIA

Products Affected

- Prolia

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Concomitant use with other medications for osteoporosis |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | <p>Treatment of postmenopausal osteoporosis/Treatment of osteoporosis in men (to increase bone mass) [a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression], approve if the patient meets one of the following: 1. has had inadequate response after 12 months of therapy with an oral bisphosphonate, had osteoporotic fracture or fragility fracture while receiving an oral bisphosphonate, or intolerability to an oral bisphosphonate, OR 2. the patient cannot take an oral bisphosphonate because they cannot swallow or have difficulty swallowing, they cannot remain in an upright position, or they have a pre-existing GI medical condition, OR 3. pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR 4. the patient has severe renal impairment (eg, creatinine clearance less than 35 mL/min) or chronic kidney disease, or if the patient has an osteoporotic fracture or fragility fracture. Treatment of bone loss in patient at high risk for fracture receiving ADT for nonmetastatic prostate cancer, approve if the patient has prostate cancer that is not metastatic to the bone and the patient is receiving ADT (eg, leuprolide, triptorelin, goserelin) or the patient has undergone a bilateral orchiectomy. Treatment of bone loss (to increase bone mass) in patients at high risk for fracture receiving adjuvant AI therapy for breast cancer, approve if the patient has breast cancer that is not metastatic to the bone and in receiving concurrent AI therapy (eg, anastrozole, letrozole,</p> |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | exemestane). Treatment of GIO, approve if pt tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or the patient cannot remain in an upright position post oral bisphosphonate administration or has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried zoledronic acid (Reclast), OR pt has severe renal impairment (CrCL less than 35 mL/min) or has CKD or has had an osteoporotic fracture or fragility fracture. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

PROMACTA

Products Affected

- Promacta

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Cause of thrombocytopenia. Thrombocytopenia due to HCV-related cirrhosis, platelet counts. Severe aplastic anemia, platelet counts and prior therapy. MDS-platelet counts. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Immune Thrombocytopenia or Aplastic Anemia, approve if prescribed by, or after consultation with, a hematologist (initial therapy). Thrombocytopenia in pt with chronic Hep C, approve if prescribed by, or after consultation with, a gastroenterologist, hematologist, hepatologist, or a physician who specializes in infectious disease (initial therapy). MDS-presc or after consult with heme/onc (initial therapy). |
| Coverage Duration | Immune thrombo/MDS initial-3 mo, cont 1 yr, AA-initial-4 mo, cont-1 yr, Thrombo/Hep C-1 yr |
| Other Criteria | Thrombocytopenia in patients with immune thrombocytopenia, initial-approve if the patient has a platelet count less than 30, 000 microliters or less than 50, 000 microliters and the patient is at an increased risk for bleeding AND the patient has tried ONE other therapy or has undergone a splenectomy. Cont-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications. Treatment of thrombocytopenia in patients with Chronic Hepatitis C initial-approve if the patient will be receiving interferon-based therapy for chronic hepatitis C AND to allow for initiation of antiviral therapy if the patient has low platelet counts at baseline (eg, less than 75,000 microliters). Aplastic anemia initial - approve if the patient has low platelet counts at baseline/pretreatment (e.g., less than 30,000 microliters) AND tried one immunosuppressant therapy (e.g., cyclosporine, mycophenolate mofetil, sirolimus) OR patient will be using Promacta in combination with standard immunosuppressive therapy. Cont-approve if the patient demonstrates a beneficial clinical response. MDS initial-approve if patient has low- to intermediate-risk MDS AND the patient has a platelet count less than 30, 000 microliters or less than 50, 000 microliters and is at an increased risk |

| PA Criteria | Criteria Details |
|--------------------------------|---|
| | for bleeding. Cont-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Thrombocytopenia in Myelodysplastic Syndrome (MDS) |
| Part B Prerequisite | No |

PYRIMETHAMINE

Products Affected

- pyrimethamine

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Patient's immune status (Toxoplasma gondii Encephalitis, chronic maintenance and prophylaxis, primary) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Toxoplasma gondii Encephalitis, Chronic Maintenance and Prophylaxis (Primary)-prescribed by or in consultation with an infectious diseases specialist. Toxoplasmosis Treatment-prescribed by or in consultation with an infectious diseases specialist, a maternal-fetal medicine specialist, or an ophthalmologist. |
| Coverage Duration | 12 months |
| Other Criteria | Toxoplasma gondii Encephalitis, Chronic Maintenance, approve if the patient is immunosuppressed. Toxoplasma gondii Encephalitis Prophylaxis (Primary), approve if the patient is immunosuppressed. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Chronic maintenance and prophylaxis of Toxoplasma Gondii encephalitis |
| Part B Prerequisite | No |

QINLOCK

Products Affected

- Qinlock

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, other therapies tried |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years |
| Other Criteria | Gastrointestinal stromal tumor (GIST), advanced-approve if, the patient has two of the following imatinib, sunitinib, Sprycel or Stivarga OR if the patient has tried Ayvakit and Sprycel. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

REPATHA

Products Affected

- Repatha
- Repatha Pushtronex
- Repatha SureClick

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use of Leqvio or Praluent. |
| Required Medical Information | LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history (as specified in the Other Criteria field) |
| Age Restrictions | ASCVD/Primary Hyperlipidemia - 18 yo and older, HoFH/HeFH - 10 yo and older. |
| Prescriber Restrictions | Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders |
| Coverage Duration | Approve for 1 year |
| Other Criteria | <p>Hyperlipidemia with HeFH - approve if: 1) diagnosis of HeFH AND 2) tried ONE high intensity statin (i.e. atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily) and LDL remains 70 mg/dL or higher unless pt is statin intolerant defined by experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin and during both trials the symptoms resolved upon discontinuation.</p> <p>Hyperlipidemia with ASCVD -approve if: 1) has one of the following conditions: prior MI, h/o ACS, diagnosis of angina, h/o CVA or TIA, PAD, undergone a coronary or other arterial revascularization procedure, AND 2) tried ONE high intensity statin (defined above) and LDL remains 70 mg/dL or higher unless pt is statin intolerant (defined above). HoFH - approve if: 1) has one of the following: a) genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus, OR b) untreated LDL greater than 500 mg/dL (prior to treatment), OR c) treated LDL greater than or equal to 300 mg/dL (after treatment but prior to agents such as Repatha or Juxtapid), OR d) has clinical manifestations of HoFH (e.g., cutaneous xanthomas, tendon xanthomas, arcus cornea, tuberous xanthomas or xanthelasma), AND 2) tried ONE high intensity statin (defined above) for 8 weeks or longer and LDL remains 70 mg/dL or</p> |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | higher unless statin intolerant (defined above). Primary hyperlipidemia (not associated with ASCVD, HeFH, or HoFH)-approve if the patient has tried one high-intensity statin therapy (defined above) and ezetimibe for 8 weeks or longer and LDL remains 100 mg/dL or higher unless statin intolerant (defined above). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

RETEVMO

Products Affected

- Retevmo oral capsule 40 mg, 80 mg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Medullary Thyroid Cancer/Thyroid Cancer-12 years and older, all others 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years |
| Other Criteria | Non-Small Cell Lung Cancer (NSCLC)-Approve if the patient has metastatic disease AND the tumor is RET fusion-positive. Medullary Thyroid Cancer-approve if the patient has advanced or metastatic RET-mutant disease and the disease requires treatment with systemic therapy. Thyroid Cancer-approve if the patient has advanced or metastatic RET fusion positive disease, the disease is radioactive iodine-refractory (if radioactive iodine is appropriate) and the disease requires treatment with systemic therapy. Anaplastic thyroid cancer-approve if the patient has RET fusion-positive anaplastic thyroid carcinoma. Solid tumors-approve if the patient has recurrent, advanced or metastatic disease and the tumor is rearranged during transfection (RET) fusion-positive. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Anaplastic thyroid carcinoma |
| Part B Prerequisite | No |

REVCovi

Products Affected

- Revcovi

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, lab values, genetic tests (as specified in the Other Criteria field) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with, an immunologist, hematologist/oncologist, or physician that specializes in ADA-SCID or related disorders. |
| Coverage Duration | 12 months |
| Other Criteria | ADA-SCID - approve if the patient had absent or very low (less than 1% of normal) ADA catalytic activity at baseline (i.e., prior to initiating enzyme replacement therapy) OR if the patient had molecular genetic testing confirming bi-allelic mutations in the ADA gene |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

REVLIMID

Products Affected

- lenalidomide
- Revlimid

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis and previous therapies or drug regimens tried. |
| Age Restrictions | 18 years and older (except Kaposi's Sarcoma, Castleman's Disease, CNS Lymphoma) |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | <p>Follicular lymphoma-approve if the patient is using lenalidomide (brand or generic) in combination with rituximab or has tried at least on prior therapy. MCL-approve -if the patient is using lenalidomide (brand or generic) in combination with rituximab or has tried at least two other therapies or therapeutic regimens. MZL-approve if the patient is using lenalidomide (brand or generic) in combination with rituximab or has tried at least one other therapy or therapeutic regimen. Multiple myeloma-approve. MDS-approve if the patient meets one of the following: 1) Pt has symptomatic anemia, OR 2) Pt has transfusion-dependent anemia, OR 3) Pt has anemia that is not controlled with an erythroid stimulating agent (eg, Epogen, Procrit [epoetin alfa injection], Aranesp [darbepoetin alfa injection]). B-cell-lymphoma (other)-approve if the pt has tried at least one prior therapy. Myelofibrosis-approve if according to the prescriber the patient has anemia and the pt has serum erythropoietin levels greater than or equal to 500 mU/mL or according to the prescriber the patient has anemia, has serum erythropoietin levels less than 500 mU/mL and patient has experienced no response or loss of response to erythropoietic stimulating agents. Peripheral T-Cell Lymphoma or T-Cell Leukemia/Lymphoma-approve if the pt has tried at least one other therapy or regimen. CNS lymphoma-approve if according to the prescriber the patient has relapsed or refractory disease. Hodgkin lymphoma, classical-</p> |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | approve if the patient has tried at least one other therapy or therapeutic regimen. Castleman's disease-approve if the patient has relapsed/refractory or progressive disease. Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and the patient has relapsed or refractory disease. Systemic light chain amyloidosis-approve if lenalidomide (brand or generic) is used in combination with dexamethasone. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Off label uses for Revlimid and lenalidomide include-Systemic Amyloidosis Light Chain, Diffuse Large B Cell Lymphoma (Non-Hodgkin's Lymphoma), Myelofibrosis. Castleman's Disease, Hodgkin lymphoma (Classical), Peripheral T-Cell Lymphoma, T-Cell Leukemia/Lymphoma, Central nervous system Lymphoma, Kaposi's sarcoma. Off label uses for lenalidomide include-follicular lymphoma, marginal zone lymphoma and multiple myeloma following autologous hematopoietic stem cell transplantation. |
| Part B Prerequisite | No |

RILUZOLE

Products Affected

- riluzole

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS. |
| Coverage Duration | 1 year |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

RINVOQ

Products Affected

- Rinvoq oral tablet extended release 24 hr
15 mg, 30 mg, 45 mg

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with a biologic or with a targeted synthetic DMARD. Concurrent use with other potent immunosuppressants. Concurrent use with an anti-interleukin monoclonal antibody, Concurrent use with other janus kinase inhibitors, or concurrent use with Xolair. |
| Required Medical Information | Diagnosis, concurrent medications, previous drugs tried. |
| Age Restrictions | PsA/RA/UC/AS-18 years and older (initial therapy), AD-12 years and older (Initial therapy) |
| Prescriber Restrictions | RA/AS/Non-Radiographic Spondy, prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or a dermatologist. AD-prescr/consult with allergist, immunologist or dermatologist. UC-prescribed by or in consultation with a gastroenterologist. |
| Coverage Duration | Approve through 12/31/23 |
| Other Criteria | RA/PsA/UC/AS initial-approve if the patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. AD-approve if the patient has had a 3 month trial of at least one traditional systemic therapy or has tried at least one traditional systemic therapy but was unable to tolerate a 3 month trial. Note: Examples of traditional systemic therapies include methotrexate, azathioprine, cyclosporine, and mycophenolate mofetil. A patient who has already tried Dupixent (dupilumab subcutaneous injection) or Adbry (tralokinumab-ldrm subcutaneous injection) is not required to step back and try a traditional systemic agent for atopic dermatitis. Non-Radiographic Axial Spondyloarthritis-approve if the patient has objective signs of inflammation defined as at least one of the following: C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory OR sacroiliitis reported on MRI and patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3- month |

| PA Criteria | Criteria Details |
|--------------------------------|---|
| | trial. Continuation Therapy - Patient must have responded, as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ROZLYTREK

Products Affected

- Rozlytrek oral capsule 100 mg, 200 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Solid Tumors-12 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Solid Tumors-Approve if the patient's tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the tumor is metastatic OR surgical resection of tumor will likely result in severe morbidity. Non-Small Cell Lung Cancer-Approve if the patient has ROS1-positive metastatic disease. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

RUBRACA

Products Affected

- Rubraca

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Rubraca is being used. BRCA-mutation (germline or somatic) status. Other medications tried for the diagnosis provided |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3years |
| Other Criteria | Ovarian, Fallopian Tube or Primary Peritoneal Cancer-treatment - Approve if the patient meets the following criteria (i and ii): i.The patient has a BRCA-mutation (germline or somatic) as confirmed by an approved test, AND ii.The patient has progressed on two or more prior lines of chemotherapy. Maintenance Therapy of Ovarian, Fallopian tube or Primary peritoneal cancer-Approve if the patient is in complete or partial response after at least two platinum-based chemotherapy regimens. Castration-Resistant Prostate Cancer - Approve if the patient meets the following criteria (A, B, C, and D): A) The patient has metastatic disease that is BRCA-mutation positive (germline and/or somatic) AND B) The patient meets one of the following criteria (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR ii. The patient has had a bilateral orchiectomy AND C) The patient has been previously treated with at least one androgen receptor-directed therapy AND D) The patient meets one of the following criteria (i or ii): i. The patient has been previously treated with at least one taxane-based chemotherapy OR ii. The patient is not a candidate or is intolerant to taxane-based chemotherapy. Uterine leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|---|
| Off-Label Uses | Uterine Leiomyosarcoma, treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer who have been treated with two or more chemotherapies |
| Part B Prerequisite | No |

RUFINAMIDE

Products Affected

- rufinamide

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Patients 1 years of age or older |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | Initial therapy-approve if rufinamide is being used for adjunctive treatment. Continuation-approve if the patient is responding to therapy |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Treatment-Refractory Seizures/Epilepsy |
| Part B Prerequisite | No |

RYDAPT

Products Affected

- Rydapt

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For AML, FLT3 status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | AML-approve if the patient is FLT3-mutation positive as detected by an approved test. Myeloid or lymphoid Neoplasms with eosinophilia-approve if the patient has an FGFR1 rearrangement or has an FLT3 rearrangement. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Myeloid or lymphoid Neoplasms with eosinophilia |
| Part B Prerequisite | No |

SAPROPTERIN

Products Affected

- sapropterin

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | Concurrent use with Palynziq |
| Required Medical Information | Diagnosis, Phe concentration |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a specialist who focuses in the treatment of metabolic diseases (initial therapy) |
| Coverage Duration | Initial-12 weeks, Continuation-1 year |
| Other Criteria | Initial - approve. Continuation (Note-if the patient has received less than 12 weeks of therapy or is restarting therapy with sapropterin should be reviewed under initial therapy) - approve if the patient has had a clinical response (e.g., cognitive and/or behavioral improvements) as determined by the prescribing physician OR patient had a 20 percent or greater reduction in blood Phe concentration from baseline OR treatment with sapropterin has resulted in an increase in dietary phenylalanine tolerance. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SCSEMBLIX

Products Affected

- Scemblix oral tablet 20 mg, 40 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Chronic Myeloid Leukemia (CML)-approve if the patient meets the following (A and B): A) Patient has Philadelphia chromosome-positive chronic myeloid leukemia, AND B) Patient meets one of the following (i or ii): i. The chronic myeloid leukemia is T315I-positive, OR ii. Patient has tried at least two other tyrosine kinase inhibitors indicated for use in Philadelphia chromosome-positive chronic myeloid leukemia. Note: Examples of tyrosine kinase inhibitors include imatinib tablets, Bosulif (bosutinib tablets), Iclusig (ponatinib tablets), Sprycel (dasatinib tablets), and Tasigna (nilotinib capsules). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SENSIPAR

Products Affected

- cinacalcet

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | Hypercalcemia d/t parathyroid CA-prescr/consult w/onco or endo. Hypercalcemia w/primary hyperparathyroidism-prescr/consult w/nephro or endo. Hyperparathyroidism in post-renal transplant-prescr/consult w/transplant physician/nephro/endo. |
| Coverage Duration | 12 months |
| Other Criteria | Hypercalcemia due to parathyroid carcinoma-approve. Hypercalcemia in patients with primary hyperparathyroidism-approve if the patient has failed or is unable to undergo a parathyroidectomy due to a contraindication. Secondary Hyperparathyroidism in patients with chronic kidney disease on dialysis - deny under Medicare Part D (claim should be submitted under the ESRD bundles payment benefit). Hyperparathyroidism in Post-Renal Transplant Patients-approve if the baseline (prior to starting cinacalcet therapy) calcium and intact parathyroid hormone (iPTH) levels are above the normal range, as defined by the laboratory reference values. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | hyperparathyroidism in post-renal transplant patients |
| Part B Prerequisite | No |

SIGNIFOR

Products Affected

- Signifor

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older (initial therapy) |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist or a physician or specializes in the treatment of Cushing's syndrome (initial therapy) |
| Coverage Duration | Cushing's disease/syndrome-Initial therapy - 4 months, Continuation therapy - 1 year. |
| Other Criteria | Cushing's disease, initial therapy - approve if, according to the prescribing physician, the patient is not a candidate for surgery, or surgery has not been curative. Cushing's disease, continuation therapy - approve if the patient has already been started on Signifor/Signifor LAR and, according to the prescribing physician, the patient has had a response and continuation of therapy is needed to maintain response. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SIRTURO

Products Affected

- Sirturo

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | Patients weighing less than 15 kg |
| Required Medical Information | Diagnosis, concomitant therapy |
| Age Restrictions | Patients 5 years of age or older |
| Prescriber Restrictions | Prescribed by, or in consultation with an infectious diseases specialist |
| Coverage Duration | 9 months |
| Other Criteria | Tuberculosis (Pulmonary) - Approve if the patient has multidrug-resistant tuberculosis and the requested medication is prescribed as part of a combination regimen with other anti-tuberculosis agents |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SKYRIZI

Products Affected

- Skyrizi subcutaneous pen injector
- Skyrizi subcutaneous syringe 150 mg/mL
- Skyrizi subcutaneous wearable injector 180 mg/1.2 mL (150 mg/mL), 360 mg/2.4 mL (150 mg/mL)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) |
| Required Medical Information | Diagnosis, Previous medication use |
| Age Restrictions | 18 years of age and older (initial therapy) |
| Prescriber Restrictions | PP-Prescribed by or in consultation with a dermatologist (initial therapy), PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD-presc/consult-gastro |
| Coverage Duration | Approve through 12/31/23 |
| Other Criteria | PP-Initial Therapy-The patient meets ONE of the following conditions (a or b): a) The patient has tried at least one traditional systemic agent for psoriasis (e.g., methotrexate [MTX], cyclosporine, acitretin tablets, or psoralen plus ultraviolet A light [PUVA]) for at least 3 months, unless intolerant. NOTE: An exception to the requirement for a trial of one traditional systemic agent for psoriasis can be made if the patient has already had a 3-month trial or previous intolerance to at least one biologic (e.g., an adalimumab product [Humira], a certolizumab pegol product [Cimzia], an etanercept product [Enbrel, Erelzi], an infliximab product [e.g., Remicade, Inflectra, Renflexis], Cosentyx [secukinumab SC injection], Ilumya [tildrakizumab SC injection], Siliq [brodalumab SC injection], Stelara [ustekinumab SC injection], Taltz [ixekizumab SC injection], or Tremfya [guselkumab SC injection]). These patients who have already tried a biologic for psoriasis are not required to 'step back' and try a traditional systemic agent for psoriasis)b) The patient has a contraindication to methotrexate (MTX), as determined by the prescribing physician.Continuation Therapy - Patient must have responded, as determined by the prescriber. Psoriatic arthritis (initial)-approve. Continuation-patient must have responded as determined by the prescriber. |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>CD, initial-approve if the patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated or if the patient has tried one other conventional systemic therapy for CD (Please note: Examples of conventional systemic therapy for Crohn's disease include azathioprine, 6-mercaptopurine, or methotrexate. An exception to the requirement for a trial of or contraindication to steroids or a trial of one other conventional systemic agent can be made if the patient has already tried at least one biologic other than the requested medication. A biosimilar of the requested biologic does not count. A trial of mesalamine does not count as a systemic agent for Crohn's disease.) or if the patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas or if the patient had ileocolonic resection (to reduce the chance of CD recurrence). Patients must be receiving an induction dosing with Skyrizi IV within 3 month of initiating therapy with Skyrizi subcutaneous. Continuation-patient must have responded as determined by the prescriber.</p> |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SOMAVERT

Products Affected

- Somavert

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous therapy, concomitant therapy |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist |
| Coverage Duration | 1 year |
| Other Criteria | Acromegaly-approve if patient meets ONE of the following (i, ii, or iii): i. patient has had an inadequate response to surgery and/or radiotherapy OR ii. The patient is NOT an appropriate candidate for surgery and/or radiotherapy OR iii. The patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) AND patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal (ULN) based on age and gender for the reporting laboratory. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SPRYCEL

Products Affected

- Sprycel oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Sprycel is being used. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. |
| Age Restrictions | GIST/chondrosarcoma or chordoma-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | For CML, patient must have Ph-positive CML. For ALL, patient must have Ph-positive ALL. GIST - approve if the patient has tried imatinib or avapritinib. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | GIST, chondrosarcoma, chordoma |
| Part B Prerequisite | No |

STELARA

Products Affected

- Stelara subcutaneous solution
- Stelara subcutaneous syringe 45 mg/0.5 mL, 90 mg/mL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD |
| Required Medical Information | Diagnosis, concurrent medications, previous drugs tried. |
| Age Restrictions | 18 years and older-UC/CD (initial therapy). PP-6 years and older (initial therapy). |
| Prescriber Restrictions | Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy). PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy). |
| Coverage Duration | Approve through 12/31/23 |
| Other Criteria | PP initial - Approve Stelara SC. CD, induction therapy - approve single dose of IV formulation if the patient meets ONE of the following criteria: 1) patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated, OR 2) patient has tried one other conventional systemic therapy for CD (eg, azathioprine, 6-MP, MTX, certolizumab, vedolizumab, adalimumab, infliximab) OR 3) patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas OR 4) patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence). UC, initial therapy-approve SC if the patient received a single IV loading dose within 2 months of initiating therapy with Stelara SC. CD, initial therapy (only after receiving single IV loading dose within 2 months of initiating therapy with Stelara SC) - approve 3 months of the SC formulation if the patient meets ONE of the following criteria: 1) patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated, OR 2) patient has tried one other agent for CD. PP/PsA/CD/UC cont - approve Stelara SC if according to the prescribing physician, the patient has responded to therapy.PP initial - approve Stelara SC. CD, initial therapy - approve 3 months of the SC formulation if the |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>patient meets ONE of the following criteria: 1) patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated, OR 2) patient has tried one other conventional systemic therapy for CD OR 3) patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas OR 4) patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence). UC, initial therapy-approve SC if the patient received a single IV loading dose within 2 months of initiating therapy with Stelara SC. PP/PsA/CD/UC cont - approve Stelara SC if according to the prescribing physician, the patient has responded to therapy.</p> |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

STIVARGA

Products Affected

- Stivarga

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Stivarga is being used. Prior therapies tried. For metastatic CRC, KRAS/NRAS mutation status. |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | For GIST, patient must have previously been treated with imatinib or Ayvakit and sunitinib or Sprycel. For HCC, patient must have previously been treated with at least one systemic regimen. Soft tissue sarcoma, advanced or metastatic disease-approve if the patient has non-adipocytic sarcoma, angiosarcoma, or pleomorphic rhabdomyosarcoma. Osteosarcoma-approve if the patient has relapsed/refractory or metastatic disease and the patient has tried one systemic chemotherapy regimen. Colon and Rectal cancer-approve if the patient has advanced or metastatic disease, has been previously treated with a fluoropyrimidine, oxaliplatin, irinotecan and if the patient's tumor or metastases are wild-type RAS, the patient has tried Erbitux or Vectibix. Glioblastoma-approve if the patient has recurrent disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Soft tissue Sarcoma, Osteosarcoma, Glioblastoma |
| Part B Prerequisite | No |

SUCRAID

Products Affected

- Sucraid

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, genetic and lab test results (as specified in the Other Criteria field) |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a geneticist, gastroenterologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of congenital diarrheal disorders |
| Coverage Duration | 1 year |
| Other Criteria | Approve if the patient has a laboratory test demonstrating deficient sucrase or isomaltase activity in duodenal or jejunal biopsy specimens OR patient has a sucrose hydrogen breath test OR has a molecular genetic test demonstrating sucrose-isomaltase mutation in saliva or blood. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SUTENT

Products Affected

- sunitinib

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Gastrointestinal stromal tumors (GIST), approve if the patient has previously tried imatinib (Gleevec). Chordoma, approve if the patient has recurrent disease. Differentiated thyroid carcinoma, approve if the patient is refractory to radioactive iodine therapy. Medullary thyroid carcinoma, approve if the patient has tried vandetanib (Caprelsa) or cabozantinib (Cometriq). Meningioma, approve if the patient has recurrent or progressive disease. Thymic carcinoma - has tried chemotherapy or radiation therapy. Renal Cell Carcinoma (RCC), clear cell or non-clear cell histology-approve if the patient is at high risk of recurrent clear cell RCC following nephrectomy and Sutent is used for adjuvant therapy or if the patient has relapsed or Stage IV disease. Neuroendocrine tumors of the pancreas-approve for advanced or metastatic disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Chordoma, angiosarcoma, solitary fibrous tumor/hemangiopericytoma, alveolar soft part sarcoma (ASPS), differentiated (ie, papillary, follicular, and Hurthle) thyroid carcinoma, medullary thyroid carcinoma, meningioma, thymic carcinoma. |
| Part B Prerequisite | No |

SYMDEKO

Products Affected

- Symdeko

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Patients with unknown CFTR gene mutations, Combination therapy with Orkambi, Kalydeco or Trikafta |
| Required Medical Information | Diagnosis, specific CFTR gene mutations |
| Age Restrictions | Six years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF |
| Coverage Duration | 3 years |
| Other Criteria | CF - must be homozygous for the F508del mutation or have at least one mutation in the CFTR gene that is responsive to the requested medication. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

SYNAREL

Products Affected

- Synarel

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Endometriosis-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Central Precocious Puberty-12 months, Endometriosis-6 months |
| Other Criteria | Central precocious puberty-approve. Endometriosis-approve if the patient has tried one of the following, unless contraindicated, a contraceptive, an oral progesterone or a depo-medroxyprogesterone injection. Note: An exception to the requirement for a trial of the above therapies can be made if the patient has previously used a gonadotropin-releasing hormone (GnRH) agonist or antagonist for endometriosis. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TABRECTA

Products Affected

- Tabrecta

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Non-Small Cell Lung Cancer (NSCLC)-Approve if the patient has metastatic disease AND the tumor is positive for a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping or high-level MET amplification, as detected by an approved test. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Non-small cell lung cancer with high-level MET amplification. |
| Part B Prerequisite | No |

TAFAMIDIS

Products Affected

- Vyndamax

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with Onpattro or Tegsedi. Concurrent use of Vyndaqel and Vyndamax. |
| Required Medical Information | Diagnosis, genetic tests and lab results (as specified in the Other Criteria field) |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | Prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis |
| Coverage Duration | 1 year |
| Other Criteria | Cardiomyopathy of Wild-Type or Hereditary Transthyretin Amyloidosis-approve if the diagnosis was confirmed by one of the following (i, ii or iii): i. A technetium pyrophosphate scan (i.e., nuclear scintigraphy),ii. Amyloid deposits are identified on cardiac biopsy OR iii. patient had genetic testing which, according to the prescriber, identified a TTR mutation AND Diagnostic cardiac imaging (e.g., echocardiogram, cardiac magnetic imaging) has demonstrated cardiac involvement (e.g., increased thickness of the ventricular wall or interventricular septum). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TAFINLAR

Products Affected

- Tafinlar

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Tafinlar is being used. BRAF V600 mutations |
| Age Restrictions | 6 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Melanoma with BRAF V600 mutation AND patient has unresectable, advanced (including Stage III or Stage IV disease) or metastatic melanoma. Note-This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery. For NSCLC, must have BRAF V600E mutation. Thyroid Cancer, anaplastic-must have BRAF V600-positive disease AND Tafinlar will be taken in combination with Mekinist, unless intolerant AND the patient has locally advanced or metastatic anaplastic disease. Thyroid Cancer, differentiated (i.e., papillary, follicular, or Hurthle cell) AND the patient has disease that is refractory to radioactive iodine therapy AND the patient has BRAF-positive disease. Biliary Tract Cancer-approve if the patient has tried at least one systemic chemotherapy regimen, patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Mekinist. Central Nervous System Cancer-approve if the medication is being used for one of the following situations (i, ii, or iii): i) adjuvant treatment of pilocytic astrocytoma OR pleomorphic xanthoastrocytoma OR ganglioglioma, OR ii) recurrent disease for one of the following: low-grade glioma OR anaplastic glioma OR glioblastoma, OR iii) melanoma with brain metastases AND patient has BRAF V600 mutation-positive disease AND medication will be taken in combination with Mekinist (trametinib tablets). Histiocytic neoplasm-approve if patient has Langerhans cell histiocytosis and one of the following: multisystem disease OR pulmonary disease OR |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | central nervous system lesions OR patient has Erdheim Chester disease AND patient has BRAF V600-mutation positive disease. Metastatic or solid tumors-approve if BRAF V600 mutation-positive disease AND medication will be taken in combination with Mekinist (trametinib tablets) AND patient has no satisfactory alternative treatment options. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Differentiated Thyroid Cancer, Biliary tract cancer, central nervous system cancer, histiocytic neoplasm |
| Part B Prerequisite | No |

TAGRISSO

Products Affected

- Tagrisso

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | NSCLC-EGFR Mutation Positive (other than EGFR T790M-Positive Mutation)- approve if the patient has advanced or metastatic disease, has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note-examples of sensitizing EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S7681. NSCLC-EGFR T790M mutation positive-approve if the patient has metastatic EGFR T790M mutation-positive NSCLC as detected by an approved test and has progressed on treatment with at least one of the EGFR tyrosine kinase inhibitors. NSCLC-Post resection-approve if the patient has completely resected stage IB-IIIa disease and has received previous adjuvant chemotherapy or if the patient is ineligible to receive platinum based chemotherapy and the patient has EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an approved test. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TALTZ

Products Affected

- Taltz Autoinjector
- Taltz Syringe

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) |
| Required Medical Information | Diagnosis, Previous medication use |
| Age Restrictions | PP-6 years and older (initial therapy), all other dx-18 years of age and older (initial therapy) |
| Prescriber Restrictions | All dx initial therapy only-PP-Prescribed by or in consultation with a dermatologist. PsA prescribed by or in consultation with a rheumatologist or a dermatologist. AS/spondylo-prescribed by or in consultation with a rheum. |
| Coverage Duration | Approve through 12/31/23 |
| Other Criteria | Initial Therapy - Plaque Psoriasis-approve if the patient has tried at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant OR the patient has a contraindication to methotrexate (MTX), as determined by the prescribing physician. An exception to the requirement for a trial of one traditional systemic agent for psoriasis can be made if the patient has already had a 3-month trial or previous intolerance to at least one biologic. PsA-Approve. AS initial-approve. Non-Radiographic Axial Spondyloarthritis-approve if the patient has objective signs of inflammation, defined as at least one of the following: C-reactive protein elevated beyond the upper limit of normal for the reporting laboratory or sacroiliitis reported on magnetic resonance imaging. Continuation Therapy - approve if the patient has responded, as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TALZENNA

Products Affected

- Talzenna oral capsule 0.25 mg, 0.5 mg, 0.75 mg, 1 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, BRCA mutation status, HER2 status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Recurrent or metastatic breast cancer-approve if the patient has germline BRCA mutation-positive AND human epidermal growth factor receptor 2 (HER2) negative disease |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TARGRETIN TOPICAL

Products Affected

- bexarotene

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, previous therapies tried |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation) |
| Coverage Duration | 3 years |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TASIGNA

Products Affected

- Tasigna oral capsule 150 mg, 200 mg, 50 mg

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Tasigna is being used. For indication of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. For indication of gastrointestinal stromal tumor (GIST) and ALL, prior therapies tried. |
| Age Restrictions | ALL/GIST/Myeloid/lymphoid neoplasms-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | For CML, patient must have Ph-positive CML. For GIST, approve if the patient has tried two of the following: imatinib, avapritinib, sunitinib, dasatinib, regorafenib or ripretinib. For ALL, Approve if the patient has tried one other tyrosine kinase inhibitor that is used for Philadelphia chromosome positive ALL (e.g., Gleevec, Sprycel, etc) and the patient has philadelphia chromosome-positive acute lymphoblastic leukemia. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement. Pigmented villonodular synovitis/tenosynovial giant cell tumor-approve if the patient has tried Turalio or cannot take Turalio, according to the prescriber. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Philadelphia positive Acute Lymphoblastic Leukemia (ALL) and Gastrointestinal Stromal Tumor (GIST), Pigmented villonodular synovitis/tenosynovial giant cell tumor, Myeloid/Lymphoid neoplasms with Eosinophilia. |
| Part B Prerequisite | No |

TAZAROTENE

Products Affected

- tazarotene topical cream
- tazarotene topical gel

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | Cosmetic uses |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | Acne vulgaris after a trial with at least 1 other topical retinoid product (eg, tretinoin cream/gel/solution/microgel, adapalene). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TAZVERIK

Products Affected

- Tazverik

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Epithelioid Sarcoma-16 years and older, Follicular Lymphoma-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Epithelioid Sarcoma-approve if the patient has metastatic or locally advanced disease and the patient is not eligible for complete resection. Follicular Lymphoma-approve if the patient has relapsed or refractory disease and according to the prescriber, there are no appropriate alternative therapies or the patient's tumor is positive for an EZH2 mutation and the patient has tried at least two prior systemic therapies. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TEPMETKO

Products Affected

- Tepmetko

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | NSCLC-approve if the patient has metastatic disease and the tumor is positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutations or patient has high-level MET amplification, as detected by an approved test. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Non-small cell lung cancer with high-level MET amplification. |
| Part B Prerequisite | No |

TERIPARATIDE

Products Affected

- teriparatide

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Concomitant use with other medications for osteoporosis |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | High risk for fracture-2 yrs, Not high risk-approve a max of 2 yrs of therapy (total)/lifetime. |
| Other Criteria | Treatment of PMO, approve if pt has tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR pt has severe renal impairment (creatinine clearance less than 35 mL/min) or CKD or pt has had an osteoporotic fracture or fragility fracture. Increase bone mass in men (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) with primary or hypogondal osteoporosis/Treatment of GIO, approve if pt tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or the patient cannot remain in an upright position post oral bisphosphonate administration or has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried zoledronic acid (Reclast), OR pt has severe renal impairment (CrCL less than 35 mL/min) or has CKD or has had an osteoporotic fracture or fragility fracture. Patients who |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | have already taken teriparatide for 2 years - approve if the patient is at high risk for fracture. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TETRABENAZINE

Products Affected

- tetrabenazine oral tablet 12.5 mg, 25 mg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | For treatment of chorea associated with Huntington's disease, Tourette syndrome or related tic disorders, hyperkinetic dystonia, or hemiballism, must be prescribed by or after consultation with a neurologist. For TD, must be prescribed by or after consultation with a neurologist or psychiatrist. |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | Chorea associated with Huntington's Disease-approve if the diagnosis of Huntington's Disease is confirmed by genetic testing. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Tardive dyskinesia (TD). Tourette syndrome and related tic disorders. Hyperkinetic dystonia. Hemiballism. |
| Part B Prerequisite | No |

THALOMID

Products Affected

- Thalomid oral capsule 100 mg, 150 mg, 200 mg, 50 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | MM, myelofibrosis-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Erythem Nodosum Leprosum-approve. Multiple Myeloma-approve. Discoid lupus erythematosus or cutaneous lupus erythematosus, approve if the patient has tried at least two other therapies (eg, corticosteroids [oral, topical, intralesional], hydroxychloroquine, tacrolimus [Protopic], methotrexate, dapson, acitretin [Soriatane]). Myelofibrosis, approve if according to the prescriber the patient has anemia and has serum erythropoietin levels greater than or equal to 500 mU/mL or if the patient has serum erythropoietin level less than 500 mU/mL and experienced no response or loss of response to erythropoietic stimulating agents. Prurigo nodularis, approve. Recurrent aphthous ulcers or aphthous stomatitis, approve if the patient has tried at least two other therapies (eg, topical or intralesional corticosteroids, systemic corticosteroids, topical anesthetics/analgesics [eg, benzocaine lozenges], antimicrobial mouthwashes [eg, tetracycline], acyclovir, colchicine). Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and has relapsed or refractory disease. Castleman's disease-approve if the patient has multicentric Castleman's disease and is negative for the human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Off-Label Uses | Discoid lupus erythematosus or cutaneous lupus erythematosus, Myelofibrosis, Prurigo nodularis, Recurrent aphthous ulcers or aphthous stomatitis, Kaposi's Sarcoma, Castleman's Disease. |
| Part B Prerequisite | No |

TIBSOVO

Products Affected

- Tibsovo

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, IDH1 Status |
| Age Restrictions | All diagnoses (except chondrosarcoma)-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | AML- approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive, as detected by an approved test. Cholangiocarcinoma-approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive and has been previously treated with at least one chemotherapy regimen (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan). Chondrosarcoma-approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Chondrosarcoma |
| Part B Prerequisite | No |

TOBRAMYCIN (NEBULIZATION)

Products Affected

- tobramycin in 0.225 % NaCl
- tobramycin inhalation

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Bronchiectasis, Non-cystic fibrosis-18 years and older |
| Prescriber Restrictions | CF-prescr/consult w/pulm/phys specializes in tx of CF.Bronchiectasis, non CF-prescr/consult w/pulm |
| Coverage Duration | 1 year |
| Other Criteria | Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Cystic fibrosis/Bronchiectasis, non-cystic fibrosis-approve if the patient has pseudomonas aeruginosa in the culture of the airway. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Bronchiectasis, non-cystic fibrosis |
| Part B Prerequisite | No |

TOLVAPTAN

Products Affected

- tolvaptan

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with Jynarque. |
| Required Medical Information | Serum sodium less than 125 mEq/L at baseline or less marked hyponatremia, defined as serum sodium less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion). |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 30 days |
| Other Criteria | Hyponatremia - Pt must meet ONE of the following: 1. serum sodium less than 125 mEq/L at baseline, OR 2. marked hyponatremia, defined as less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion), OR 3. patient has already been started on tolvaptan and has received less than 30 days of therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TOPICAL AGENTS FOR ATOPIC DERMATITIS

Products Affected

- pimecrolimus
- tacrolimus topical

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | Authorize use in patients who have tried a prescription strength topical corticosteroid (brand or generic) for the current condition. Dermatologic condition on or around the eyes, eyelids, axilla, or genitalia, authorize use without a trial of a prescription strength topical corticosteroid. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TOPICAL RETINOID PRODUCTS

Products Affected

- Avita topical cream
- tretinoin topical

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | Coverage is not provided for cosmetic use. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TOPIRAMATE/ZONISAMIDE

Products Affected

- Eprontia
- topiramate oral capsule, sprinkle
- topiramate oral tablet
- Zonisade
- zonisamide

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Coverage is not provided for weight loss or smoking cessation. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 1 year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TRANSDERMAL FENTANYL

Products Affected

- fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Acute (i.e., non-chronic) pain. |
| Required Medical Information | Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 1 year |
| Other Criteria | For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been tried and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 5) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, sickle cell disease, in hospice or who reside in a long term care facility are not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids (including transdermal fentanyl products) require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

TRANSMUCOSAL FENTANYL DRUGS

Products Affected

- fentanyl citrate buccal lozenge on a handle

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 12 months. |
| Other Criteria | For breakthrough pain in patients with cancer if patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting OR patient is unable to take 2 other short-acting narcotics (eg, oxycodone, morphine sulfate, hydromorphone, etc) secondary to allergy or severe adverse events AND patient is on or will be on a long-acting narcotic (eg, Duragesic), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate). Clinical criteria incorporated into the quantity limit edits for all transmucosal fentanyl drugs require confirmation that the indication is breakthrough cancer pain (ie, FDA labeled use) prior to reviewing for quantity exception. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TRIENTINE

Products Affected

- trientine

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, medication history, pregnancy status, disease manifestations |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician. |
| Coverage Duration | Authorization will be for 1 year |
| Other Criteria | For Wilson's Disease, approve if the patient meets A and B: A) Diagnosis of Wilson's disease is confirmed by ONE of the following (i or ii): i. Genetic testing results confirming biallelic pathogenic ATP7B mutations (in either symptomatic or asymptomatic individuals), OR ii. Confirmation of at least two of the following (a, b, c, or d): a. Presence of Kayser-Fleischer rings, OR b. Serum ceruloplasmin levels less than 20mg/dL, OR c. Liver biopsy findings consistent with Wilson's disease, OR d. 24-hour urinary copper greater than 40 micrograms/24 hours, AND B) Patient meets ONE of the following: 1) Patient has tried a penicillamine product and per the prescribing physician the patient is intolerant to penicillamine therapy, OR 2) Per the prescribing physician, the patient has clinical features indicating the potential for intolerance to penicillamine therapy (ie, history of any renal disease, congestive splenomegaly causing severe thrombocytopenia, autoimmune tendency), OR 3) Per the prescribing physician, the patient has a contraindication to penicillamine therapy, OR 4) The patient has neurologic manifestations of Wilson's disease, OR 5) The patient is pregnant, OR 6) the patient has been started on therapy with trientine. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

TRIKAFTA

Products Affected

- Trikafta

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patients with unknown CFTR gene mutations. Combination therapy with Orkambi, Kalydeco or Symdeko. |
| Required Medical Information | Diagnosis, specific CFTR gene mutations, concurrent medications |
| Age Restrictions | Six years of age and older |
| Prescriber Restrictions | Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF |
| Coverage Duration | 3 years |
| Other Criteria | CF - must have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive to the requested medication. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TRUSELTIQ

Products Affected

- Truseltiq oral capsule 100 mg/day (100 mg x 1), 125 mg/day (100 mg x 1-25mg x 1), 50 mg/day (25 mg x 2), 75 mg/day (25 mg x 3)

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Cholangiocarcinoma-approve if the patient has unresectable locally advanced or metastatic disease, has fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an approved test and Truseltiq will be used as subsequent therapy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TUKYSA

Products Affected

- Tukysa oral tablet 150 mg, 50 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapies |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Breast Cancer-approve if the patient has advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive disease, has received at least one prior anti-HER2-based regimen in the metastatic setting and Tukysa is used in combination with trastuzumab and capecitabine. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

TURALIO

Products Affected

- Turalio oral capsule 200 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis)-approve if, according to the prescriber, the tumor is not amenable to improvement with surgery. Histiocytic Neoplasms-approve if the patient has a colony stimulating factor 1 receptor (CSF1R) mutation AND has one of the following conditions (i, ii, or iii): i. Langerhans cell histiocytosis OR ii. Erdheim-Chester disease OR iii. Rosai-Dorfman disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Histiocytic Neoplasms |
| Part B Prerequisite | No |

VALCHLOR

Products Affected

- Valchlor

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Cutaneous lymphoma-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Cutaneous Lymphomas (Note-includes mycosis fungoides/Sezary syndrome, primary cutaneous B-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders)-approve. Adult T-Cell Leukemia/Lymphoma-approve if the patient has chronic/smoldering subtype of adult T-cell leukemia/lymphoma. Langerhans cell histiocytosis-approve if the patient has unifocal Langerhans cell histiocytosis with isolated skin disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Adults with T-cell leukemia/lymphoma, Langerhans Cell Histiocytosis |
| Part B Prerequisite | No |

VALTOCO

Products Affected

- Valtoco

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, other medications used at the same time |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist |
| Coverage Duration | 1 year |
| Other Criteria | Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiepileptic medication(s). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VANCOMYCIN

Products Affected

- vancomycin oral capsule 125 mg, 250 mg

| PA Criteria | Criteria Details |
|------------------------------|-------------------------------|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 2 weeks |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VENCLEXTA

Products Affected

- Venclexta oral tablet 10 mg, 100 mg, 50 mg
- Venclexta Starting Pack

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapy |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | <p>Chronic Lymphocytic Leukemia, new starts: Approve if the patient meets one of the following (i, ii, iii, iv, v, or vi): i. Patient has tried Imbruvica (Note: A trial of another BTK inhibitor also counts), OR ii. Patient is using or is planning to use the requested agent in combination with Gazyva (obinutuzumab intravenous infusion) or rituximab, OR iii. patient is at an increased risk of bleeding, OR iv. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR v. Patient has hypertension, OR vi. Patient has experienced or is at risk for secondary primary malignancies (Note: An example is skin cancer). Small Lymphocytic Lymphoma, new starts: Approve if the patient meets one of the following (i, ii, iii, iv, v, or vi): i. Patient has tried Imbruvica (Note: A trial of another BTK inhibitor also counts), OR ii. Patient is using or is planning to use the requested agent in combination with Gazyva (obinutuzumab intravenous infusion) or rituximab, OR iii. patient is at an increased risk of bleeding, OR iv. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR v. Patient has hypertension, OR vi. Patient has experienced or is at risk for secondary primary malignancies (Note: An example is skin cancer). Mantle Cell Lymphoma, new starts: Approve if the patient meets one of the following (i, ii, iii, iv, v or vi): i. Patient has tried Imbruvica (Note: A trial of another BTK inhibitor also counts), OR ii. Patient is using or is planning to use the requested agent in combination with Imbruvica or rituximab, OR iii. patient</p> |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>is at an increased risk of bleeding, OR iv. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR v. Patient has hypertension, OR vi. Patient has experienced or is at risk for secondary primary malignancies. (Note: An example is skin cancer). Acute Myeloid Leukemia, new starts: Approve. Multiple Myeloma, new starts: Approve. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: Approve if the patient meets one of the following (i, ii, iii, iv, or v): i. Patient has tried Imbruvica (Note: A trial of another BTK inhibitor also counts), OR ii. patient is at an increased risk of bleeding, OR iii. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR iv. Patient has hypertension, OR v. Patient has experienced or is at risk for secondary primary malignancies (Note: An example is skin cancer). For all covered diagnoses, if patients have been started on Venclexta patients are allowed to continue therapy without a trial of Imbruvica.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Mantle Cell Lymphoma, waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, multiple myeloma |
| Part B Prerequisite | No |

VERZENIO

Products Affected

- Verzenio

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | HR status, HER2 status, previous medications/therapies tried, concomitant therapy, menopausal status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Breast cancer, early-approve for 2 years, all other-3 years |
| Other Criteria | <p>Breast Cancer, Early-Approve if pt meets (A,B,C and D): A)Pt has HR+disease, AND B)Pt has HER2-negative breast cancer, AND C)Pt meets the following:Pt has node-positive disease at high risk of recurrence (Note-High risk includes patients with greater than or equal to 4 positive lymph nodes, or 1-3 positive lymph nodes with one or more of the following: Grade 3 disease, tumor size greater than or equal to 5 cm, or a Ki-67 score of greater than or equal to 20percent) AND D)Pt meets ONE of the following (i or ii): i.Verzenio will be used in combo w/anastrozole, exemestane, or letrozole AND pt meets one of the following (a,b, or c): a)Pt is a postmenopausal woman, OR b)Pt is a pre/perimenopausal woman and meets one of the following 1 or 2:1-Pt is receiving ovarian suppression/ablation with a gonadotropin-releasing hormone (GnRH) agonist, OR 2-Pt has had surgical bilateral oophorectomy or ovarian irradiation, OR c)Pt is a man and pt is receiving a GnRH analog, OR ii.Verzenio will be used in combo with tamoxifen AND pt meets one of the following (a or b): a)Pt is a postmenopausal woman or man OR b)Pt is a pre/perimenopausal woman and meets one of the following 1 or 2:1-Pt is receiving ovarian suppression/ablation with a GnRH agonist, OR 2-Patient has had surgical bilateral oophorectomy or ovarian irradiation. Breast Cancer-Recurrent or Metastatic in Women-Approve if pt meets (A, B, C and D): A) Pt has HR+ disease, AND B)Pt has HER2-negative breast cancer, AND C)Pt meets ONE of the following criteria (i or ii): i.Pt is a</p> |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | <p>postmenopausal woman, OR ii. Pt is a pre/perimenopausal woman and meets one of the following (a or b): a) Pt is receiving ovarian suppression/ablation with a GnRH agonist, OR b) Pt has had surgical bilateral oophorectomy or ovarian irradiation, AND D) Pt meets ONE of the following criteria (i, ii, or iii): i. Verzenio will be used in combo with anastrozole, exemestane, or letrozole, OR ii. Verzenio will be used in combo with fulvestrant, OR iii. pt meets the following conditions (a, b, and c): a) Verzenio will be used as monotherapy, AND b) Pt's breast cancer has progressed on at least one prior endocrine therapy, AND c) Pt has tried chemotherapy for metastatic breast cancer. Breast Cancer-Recurrent or Metastatic in Men-Approve if pt meets the following criteria (A,B and C): A) Pt has HR+ disease, AND B) Pt has HER2-negative breast cancer, AND C) Pt meets ONE of the following criteria (i, ii, or iii): i. Pt meets BOTH of the following conditions (a and b): a) Pt is receiving a GnRH analog, AND b) Verzenio will be used in combo with anastrozole, exemestane, or letrozole, OR ii. Verzenio will be used in combo with fulvestrant, OR iii. Pt meets the following conditions (a, b, and c): a) Verzenio will be used as monotherapy, AND b) Pt's breast cancer has progressed on at least one prior endocrine therapy, AND c) Pt has tried chemotherapy for metastatic breast cancer.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | treatment of advanced or metastatic breast cancer in combination with an aromatase inhibitor in pre-menopausal women |
| Part B Prerequisite | No |

VITRAKVI

Products Affected

- Vitrakvi oral capsule 100 mg, 25 mg
- Vitrakvi oral solution

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, NTRK gene fusion status |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Solid tumors - approve if the tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the tumor is metastatic or surgical resection of tumor will likely result in severe morbidity. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VIZIMPRO

Products Affected

- Vizimpro

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, EGFR status, exon deletions or substitutions |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | NSCLC-approve if the patient has advanced or metastatic disease, has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: Examples of sensitizing EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S7681. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VONJO

Products Affected

- Vonjo

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Myelofibrosis (MF), including primary MF, post-polycythemia Vera MF, and Post-Essential Thrombocythemia MF-approve if the patient has intermediate risk or high risk disease and the patient has a platelet count of less than $50 \times 10^9/L$ (less than 50,000/mcL) |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

VORICONAZOLE (ORAL)

Products Affected

- voriconazole

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Aspergillus-Prophy, systemic w/risk neutropenia-Prophy, systemic w/HIV-Prophy/Tx-6 mo, others-3 mo |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Aspergillus Infections - prophylaxis, oropharyngeal candidiasis (fluconazole-refractory) - treatment, candidia endophthalmitis - treatment, blastomycosis - treatment, fungal infections (systemic) in patients at risk of neutropenia - prophylaxis, fungal infections (systemic) in patients with human immunodeficiency virus (HIV) - prophylaxis or treatment. |
| Part B Prerequisite | No |

VOSEVI

Products Affected

- Vosevi

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Genotype, prescriber specialty, other medications tried or used in combination with requested medication |
| Age Restrictions | 18 years or older |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician |
| Coverage Duration | Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug |
| Other Criteria | Criteria will be applied consistent with current AASLD/IDSA guidance. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Indications consistent with current AASLD/IDSA guidance |
| Part B Prerequisite | No |

VOTRIENT

Products Affected

- Votrient

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Soft tissue sarcoma other than GIST [angiosarcoma, Pleomorphic rhabdomyosarcoma, retroperitoneal/intra-abdominal soft tissue sarcoma that is unresectable or progressive, soft tissue sarcoma of the extremity/superficial trunk or head/neck, including synovial sarcoma, or solitary fibrous tumor/hemangiopericytoma or alveolar soft part sarcoma], approve. Differentiated (ie, papillary, follicular, Hurthle) thyroid carcinoma, approve if the patient is refractory to radioactive iodine therapy. Uterine sarcoma, approve if the patient has recurrent, advanced or metastatic disease. Renal Cell Carcinoma, Clear Cell or non-Clear Cell histology-approved if the patient has relapsed or stage IV disease. Ovarian Cancer (ie, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer) - approve if the patient has persistent or recurrent disease. GIST - approve if the patient has tried TWO of the following: Gleevec, Sutent, or Stivarga. Medullary Thyroid Carcinoma, approve if the patient has tried vandetanib (Caprelsa) or cabozantinib (Cometriq). |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Differentiated (ie, papillary, follicular, Hurthle cell) thyroid carcinoma. Uterine sarcoma, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Gastrointestinal Stromal Tumor (GIST), Medullary thyroid carcinoma. |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

WELIREG

Products Affected

- Welireg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Van Hippel-Lindau Disease-approve if the patient meets the following (A, B, and C): A) Patient has a von Hippel-Lindau (VHL) germline alteration as detected by genetic testing, B) Does not require immediate surgery and C) Patient requires therapy for ONE of the following conditions (i, ii, iii, or iv): i. Central nervous system hemangioblastomas, OR ii. Pancreatic neuroendocrine tumors, OR iii. Renal cell carcinoma, OR iv. Retinal hemangioblastoma. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XALKORI

Products Affected

- Xalkori

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | Anaplastic large cell lymphoma-patients greater than or equal to 1 year of age. All other diagnoses (except soft tissue sarcoma)-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Metastatic non-small cell lung cancer-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease, as detected by an approved test or ROS1 rearrangement positive disease, as detected by an approved test. Metastatic non-small cell lung cancer-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease, as detected by an approved test or ROS1 rearrangement positive disease, as detected by an approved test. Anaplastic Large Cell Lymphoma-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease AND has received at least one prior systemic treatment. Histiocytic neoplasm-approve if the patient has ALK rearrangement/fusion-positive disease and meets one of the following criteria (i, ii, or iii): (i. Patient has Langerhans cell histiocytosis, OR ii. Patient has Erdheim-Chester disease OR iii. Patient has Rosai-Dorfman disease. NSCLC with MET mutation-approve if the patient has high level MET amplification or MET exon 14 skipping mutation. Soft Tissue Sarcoma - Inflammatory Myofibroblastic Tumor with Anaplastic Lymphoma Kinase (ALK) Translocation-approve. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | NSCLC with high level MET amplification or MET Exon 14 skipping mutation, Histiocytic neoplasms. |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

XELJANZ

Products Affected

- Xeljanz oral solution
- Xeljanz oral tablet
- Xeljanz XR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with a biologic or with a Targeted Synthetic DMARD for an inflammatory condition (eg, tocilizumab, anakinra, abatacept, rituximab, certolizumab pegol, etanercept, adalimumab, infliximab, golimumab). Concurrent use with potent immunosuppressants that are not methotrexate (MTX) [eg, azathioprine, tacrolimus, cyclosporine, mycophenolate mofetil]. |
| Required Medical Information | Diagnosis, concurrent medications, previous drugs tried. |
| Age Restrictions | AS/PsA/RA/UC-18 years and older (initial therapy) |
| Prescriber Restrictions | RA, JIA/JRA/AS prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or a dermatologist. UC-prescribed by or in consultation with a gastroenterologist. |
| Coverage Duration | Approve through 12/31/23 |
| Other Criteria | RA initial-approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. PsA initial, approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial and the requested medication will be used in combination with methotrexate or another conventional synthetic disease modifying antirheumatic drug (DMARD), unless contraindicated. UC- Approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least ONE tumor necrosis factor inhibitor for ulcerative colitis or was unable to tolerate a 3-month trial. Juvenile Idiopathic Arthritis (JIA) [or Juvenile Rheumatoid Arthritis] (regardless of type of onset) [Note: This includes patients with juvenile spondyloarthropathy/active sacroiliac arthritis]-initial-approve Xeljanz immediate release tablets or solution if the patient meets the following: patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. AS-approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. Continuation Therapy - Patient must have responded, as determined by the prescriber. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XOLAIR

Products Affected

- Xolair subcutaneous recon soln
- Xolair subcutaneous syringe 150 mg/mL, 75 mg/0.5 mL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with an Interleukin (IL) Antagonist Monoclonal Antibody |
| Required Medical Information | Moderate to severe persistent asthma, baseline IgE level of at least 30 IU/mL. For asthma, patient has a baseline positive skin test or in vitro testing (ie, a blood test for allergen-specific IgE antibodies such as an enzyme-linked immunoabsorbant assay (eg, immunoCAP, ELISA) or the RAST) for 1 or more perennial aeroallergens (eg, house dust mite, animal dander [dog, cat], cockroach, feathers, mold spores) and/or for 1 or more seasonal aeroallergens (grass, pollen, weeds). CIU - must have urticaria for more than 6 weeks (prior to treatment with Xolair), with symptoms present more than 3 days/wk despite daily non-sedating H1-antihistamine therapy (e.g., cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine). |
| Age Restrictions | Moderate to severe persistent asthma-6 years and older. CIU-12 years and older. Polyps-18 years and older |
| Prescriber Restrictions | Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist. Polyps-prescribed by or in consult with an allergist, immunologist, or otolaryngologist |
| Coverage Duration | asthma/CIU-Initial tx 4 months, Polyps-initial-6 months, continued tx 12 months |
| Other Criteria | Moderate to severe persistent asthma approve if pt meets criteria 1 and 2: 1) pt has received at least 3 months of combination therapy with an inhaled corticosteroid and at least one the following: long-acting beta-agonist (LABA), long-acting muscarinic antagonist (LAMA), leukotriene receptor antagonist, or theophylline, and 2)patient's asthma is uncontrolled or was uncontrolled prior to receiving any Xolair or anti-IL-4/13 therapy (Dupixent) therapy as defined by ONE of the following (a, b, c, d, or e): a) The patient experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year OR b) The patient experienced one or more asthma exacerbation requiring |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>hospitalization or an Emergency Department (ED) visit in the previous year OR c) Patient has a forced expiratory volume in 1 second (FEV1) less than 80 percent predicted OR d) Patient has an FEV1/forced vital capacity (FVC) less than 0.80 OR e) The patient's asthma worsens upon tapering of oral corticosteroid therapy NOTE: An exception to the requirement for a trial of one additional asthma controller/maintenance medication can be made if the patient has already received anti-IL-4/13 therapy (Dupixent) used concomitantly with an ICS. For continued Tx for asthma - patient has responded to therapy as determined by the prescribing physician and continues to receive therapy with one inhaled corticosteroid or inhaled corticosteroid containing combination product. For CIU cont tx - must have responded to therapy as determined by the prescribing physician. Nasal Polyps Initial-Approve if the patient has a baseline IgE level greater than or equal to 30 IU/ml, patient is experiencing significant rhinosinusitis symptoms such as nasal obstruction, rhinorrhea, or reduction/loss of smell and patient is currently receiving therapy with an intranasal corticosteroid. Nasal polyps continuation-approve if the patient continues to receive therapy with an intranasal corticosteroid and has responded to therapy.</p> |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XOSPATA

Products Affected

- Xospata

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, FLT3-mutation status |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | AML - approve if the patient has relapsed or refractory disease AND the disease is FLT3-mutation positive as detected by an approved test. Lymphoid, Myeloid Neoplasms-approve if the patient has eosinophilia and the disease is FLT3-mutation positive as detected by an approved test. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Lymphoid, Myeloid Neoplasms |
| Part B Prerequisite | No |

XPOVIO

Products Affected

- Xpovio oral tablet 100 mg/week (50 mg x 1), 60mg twice week (120 mg/week), 80 mg/week (40 mg x 2), 40 mg/week (40 mg x 1), 40mg twice week (40 mg x 2), 60 mg/week (60 mg x 1), 80mg twice week (80 mg x 2), 160mg twice week (160 mg/week)

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, prior therapies |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Multiple Myeloma-Approve if the patient meets the following (A and B): A) The medication will be taken in combination with dexamethasone AND B) Patient meets one of the following (i, ii, or iii): i. Patient has tried at least four prior regimens for multiple myeloma OR ii. Patient meets both of the following (a and b): a) Patient has tried at least one prior regimen for multiple myeloma AND b) The medication will be taken in combination with bortezomib OR iii. Patient meets both of the following (a and b): a) Patient has tried at least one prior regimen for multiple myeloma AND b) The medication will be taken in combination with Darzalex (daratumumab infusion), Darzlaex Faspro (daratumumab and hyaluronidase-fihj injection), or Pomalyst (pomalidomide capsules). Note: Examples of regimens for multiple myeloma include bortezomib/Revlimid (lenalidomide capsules)/dexamethasone, Kyprolis (carfilzomib infusion)/Revlimid/dexamethasone, Darzalex (daratumumab injection)/bortezomib or Kyprolis/dexamethasone, or other regimens containing a proteasome inhibitor, immunomodulatory drug, and/or anti-CD38 monoclonal antibody. Diffuse large B-cell lymphoma-approve if the patient has been treated with at least two prior systemic therapies. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|----------------------------|--|
| Off-Label Uses | Treatment of multiple myeloma in combination with daratumumb or pomalidomide |
| Part B Prerequisite | No |

XTANDI

Products Affected

- Xtandi oral capsule
- Xtandi oral tablet 40 mg, 80 mg

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis for which Xtandi is being used. |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Prostate cancer-castration-resistant [Metastatic or Non-metastatic] and Prostate cancer-metastatic, castration sensitive-approve if Xtandi will be used concurrently with a gonadotropin-releasing hormone (GnRH) agonist or the medication is concurrently used with Firmagon or if the patient has had a bilateral orchiectomy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

XYREM

Products Affected

- Xyrem

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use of sodium oxybate, Xywav, Wakix, Sunosi |
| Required Medical Information | Medication history |
| Age Restrictions | 7 years and older |
| Prescriber Restrictions | Prescribed by a sleep specialist physician or a Neurologist |
| Coverage Duration | 12 months. |
| Other Criteria | For Excessive daytime sleepiness (EDS) in patients with narcolepsy, 18 years and older - approve if the patient has tried one CNS stimulant (e.g., methylphenidate, dextroamphetamine), modafinil, or armodafinil and narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). For EDS in patients with narcolepsy, less than 18 years old-approve if the patient has tried one CNS stimulant (e.g., methylphenidate, dextroamphetamine) or modafinil and narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). Cataplexy treatment in patients with narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

YONSA

Products Affected

- Yonsa

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis, concomitant medications |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Metastatic castration-resistant prostate cancer (mCRPC) - approve if the patient will be using Yonsa in combination with methylprednisolone or dexamethasone and the patient meets ONE of the following criteria (i or ii): i. The medication is concurrently used with a gonadotropin-releasing hormone (GnRH) analog OR ii. The patient has had a bilateral orchiectomy. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ZEJULA

Products Affected

- Zejula

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | 18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Ovarian, fallopian tube, or primary peritoneal cancer, maintenance therapy - approve if the patient is in complete or partial response after platinum-based chemotherapy regimen. Ovarian, fallopian tube, or primary peritoneal cancer, treatment-approve per label if the patient has tried at least three prior chemotherapy regimens and has homologous recombination deficiency (HRD)-positive disease as confirmed by an approved test. Uterine leiomyosarcoma-approve if the patient has BRCA2 mutation and has tried one systemic regimen. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Uterine Leiomyosarcoma |
| Part B Prerequisite | No |

ZELBORAF

Products Affected

- Zelboraf

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | BRAFV600 mutation status required. |
| Age Restrictions | CNS Cancer-3 years and older, all other-18 years and older |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Melanoma, patient new to therapy must have BRAFV600 mutation for approval AND have unresectable, advanced or metastatic melanoma. HCL - must have tried at least one other systemic therapy for hairy cell leukemia. Thyroid Cancer-patient has disease that is refractory to radioactive iodine therapy. Erdheim-Chester disease, in patients with the BRAF V600 mutation-approve. Central Nervous System Cancer-approve if the patient has BRAF V600 mutation-positive disease AND medication is being used for one of the following situations (i, ii, or iii): i) adjuvant treatment of pilocytic astrocytoma OR pleomorphic xanthoastrocytoma OR ganglioglioma, OR ii) recurrent disease for one of the following conditions: low-grade glioma OR anaplastic glioma OR glioblastoma, OR iii) melanoma with brain metastases AND the medication will be taken in combination with Cotellic (cobimetinib tablets). Histiocytic Neoplasm-approve if the patient has Langerhans cell histiocytosis and one of the following: multisystem disease OR pulmonary disease OR central nervous system lesions AND the patient has BRAF V600-mutation positive disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Patients with Hairy Cell Leukemia, Non-Small Cell Lung Cancer (NSCLC) with BRAF V600E Mutation, Differentiated thyroid carcinoma (i.e., papillary, follicular, or Hurthle cell) with BRAF-positive disease, Central Nervous System Cancer, Histiocytic Neoplasm |

| PA Criteria | Criteria Details |
|------------------------|------------------|
| Part B Prerequisite | No |

ZOLINZA

Products Affected

- Zolinza

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Diagnosis |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | 3 years |
| Other Criteria | Cutaneous T-Cell Lymphoma including Mycosis Fungoides/Sezary Syndrome-approve. |
| Indications | All FDA-approved Indications. |
| Off-Label Uses | N/A |
| Part B Prerequisite | No |

ZYDELIG

Products Affected

- Zydelig

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | <p>Chronic Lymphocytic Leukemia, new to therapy: Approve if the patient meets one of the following (i, ii, iii, iv, or v): i. Patient has tried Imbruvica (Note: A trial of another BTK inhibitor AND Venclexta also counts), OR ii. patient is at risk of bleeding, OR iii. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR iv. Patient has hypertension, OR v. Patient has experienced or is at increased risk for secondary primary malignancies (Note: An example is skin cancer). Small Lymphocytic Lymphoma: Approve if the patient meets one of the following (i, ii, iii, iv, or v): i Patient has tried Imbruvica (Note: A trial of another BTK inhibitor AND Venclexta also counts), OR ii. patient is at risk of bleeding, OR iii. patient has atrial fibrillation/atrial flutter or is at risk for atrial fibrillation/atrial flutter, OR iv. Patient has hypertension, OR v. Patient has experienced or is at increased risk for secondary primary malignancies (Note: An example is skin cancer). Patients currently receiving therapy with Zydelig: Approve.</p> |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | small lymphocytic lymphoma |
| Part B Prerequisite | No |

ZYKADIA

Products Affected

- Zykadia

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Must have metastatic NSCLC that is anaplastic lymphoma kinase (ALK)-positive as detected by an approved test or ROS1 Rearrangement. IMT - ALK Translocation status. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Erdheim-Chester Disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Soft Tissue Sarcoma Inflammatory Myofibroblastic Tumor (IMT) with ALK Translocation. Patients with NSCLC with ROS1 Rearrangement. Erdheim-Chester disease. |
| Part B Prerequisite | No |

ZYTIGA

Products Affected

- abiraterone oral tablet 250 mg, 500 mg

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Authorization will be for 3 years. |
| Other Criteria | Prostate Cancer-Metastatic, Castration-Resistant (mCRPC)-Approve if abiraterone is being used in combination with prednisone or dexamethasone and the medication is concurrently used with a gonadotropin-releasing hormone (GnRH) agonist, or the medication is concurrently used with Firmagon or the patient has had a bilateral orchiectomy. Prostate cancer-metastatic, castration-sensitive (mCSPC)-approve if the medication is used in combination with prednisone and the medication is concurrently used with a GnRH agonist or concurrently used with Firmagon or the patient has had a bilateral orchiectomy. Prostate Cancer - Regional Risk Group - Approve if the patient meets all of the following criteria (A, B, and C): A)abiraterone is used in combination with prednisone AND B) Patient has regional lymph node metastases and no distant metastases AND C) Patient meets one of the following criteria (i, ii or iii): i.abiraterone with prednisone is used in combination with GnRH agonist OR ii. Patient has had a bilateral orchiectomy OR iii. the medication is used in combination with Firmagon. Prostate cancer-very-high-risk-group-approve if according to the prescriber the patient is in the very-high-risk group, the medication will be used in combination with external beam radiation therapy and the patient meets one of the following criteria (i, ii or iii): i. abiraterone is used in combination with GnRH agonist OR ii. Patient has had a bilateral orchiectomy OR iii. the medication is used in combination with Firmagon. Prostate cancer-radical |

| PA Criteria | Criteria Details |
|----------------------------|--|
| | prostatectomy-approve if the medication is used in combination with prednisone, the patient has prostate specific antigen (PSA) persistence or recurrence following radical prostatectomy, patient has pelvic recurrence, the medication will be used concurrently with GnRH agonist, Firmagon or the patient has had a bilateral orchiectomy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off-Label Uses | Prostate Cancer-Regional Risk Group, Prostate cancer-very-high-risk group, Prostate cancer-radical prostatectomy |
| Part B Prerequisite | No |

PART B VERSUS PART D

Products Affected

- Abelcet
- acetylcysteine
- Actimmune
- acyclovir sodium intravenous solution
- albuterol sulfate inhalation solution for nebulization 0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg /3 mL (0.083 %), 2.5 mg/0.5 mL
- amphotericin B
- aprepitant
- arformoterol
- azathioprine oral tablet 50 mg
- budesonide inhalation suspension for nebulization 0.25 mg/2 mL, 0.5 mg/2 mL, 1 mg/2 mL
- Clinimix 5%/D15W Sulfite Free
- Clinimix 4.25%/D10W Sulf Free
- Clinimix 4.25%/D5W Sulfite Free
- Clinimix 5%-D20W(sulfite-free)
- cromolyn inhalation
- cyclophosphamide oral capsule
- cyclophosphamide oral tablet
- cyclosporine modified
- cyclosporine oral capsule
- dronabinol
- Engerix-B (PF)
- Engerix-B Pediatric (PF)
- everolimus (immunosuppressive)
- Firmagon kit w diluent syringe
- formoterol fumarate
- Gengraf
- granisetron HCl oral
- Intralipid intravenous emulsion 20 %
- ipratropium bromide inhalation
- ipratropium-albuterol
- methotrexate sodium
- methotrexate sodium (PF) injection solution
- methylprednisolone oral tablet
- mycophenolate mofetil
- mycophenolate sodium
- ondansetron
- ondansetron HCl oral solution
- ondansetron HCl oral tablet 4 mg, 8 mg
- pentamidine inhalation
- Plenamine
- Prehevbrio (PF)
- Premasol 10 %
- Prograf oral granules in packet
- Pulmozyme
- Recombivax HB (PF)
- Sandimmune oral solution
- sirolimus
- Synribo
- tacrolimus oral
- Travasol 10 %
- Trelstar intramuscular suspension for reconstitution
- TrophAmine 10 %
- Xatmep
- Xgeva

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Index

A

| | |
|---|----------|
| Abelcet | 273 |
| abiraterone oral tablet 250 mg, 500 mg . | 271, 272 |
| acetylcysteine | 273 |
| Actemra ACTPen..... | 1, 2 |
| Actemra subcutaneous | 1, 2 |
| Actimmune..... | 273 |
| acyclovir sodium intravenous solution ... | 273 |
| acyclovir topical ointment..... | 3 |
| Adempas | 4 |
| albuterol sulfate inhalation solution for nebulization 0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg /3 mL (0.083 %), 2.5 mg/0.5 mL | 273 |
| Alecensa | 5 |
| alosetron | 122 |
| Alunbrig oral tablet 180 mg, 30 mg, 90 mg | 7 |
| Alunbrig oral tablets,dose pack..... | 7 |
| Amabelz | 85 |
| ambrisentan | 22 |
| amikacin injection solution 500 mg/2 mL . | 9, 10 |
| amphotericin B..... | 273 |
| ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg | 9, 10 |
| ampicillin-sulbactam injection..... | 9, 10 |
| aprepitant..... | 273 |
| Arcalyst | 12 |
| arformoterol | 273 |
| Arikayce..... | 13, 14 |
| armodafinil | 131 |
| Avita topical cream | 227 |
| Ayvakit..... | 15 |
| azathioprine oral tablet 50 mg..... | 273 |
| azithromycin intravenous..... | 9, 10 |
| aztreonam | 9, 10 |

B

| | |
|---------------------------------|---------|
| Balversa..... | 16 |
| Benlysta subcutaneous | 17, 18 |
| benztropine oral | 81 |
| Besremi | 19 |
| Betaseron subcutaneous kit..... | 20 |
| bexarotene | 21, 213 |

| | |
|---|-------|
| Bicillin L-A..... | 9, 10 |
| Bosulif oral tablet 100 mg, 400 mg, 500 mg | 23 |
| Braftovi oral capsule 75 mg..... | 24 |
| Brukinsa | 25 |
| budesonide inhalation suspension for nebulization 0.25 mg/2 mL, 0.5 mg/2 mL, 1 mg/2 mL..... | 273 |
| Bydureon BCise | 73 |
| Byetta subcutaneous pen injector 10 mcg/dose(250 mcg/mL) 2.4 mL, 5 mcg/dose (250 mcg/mL) 1.2 mL | 73 |

C

| | |
|--|--------|
| Cablivi injection kit..... | 27 |
| Cabometyx | 28 |
| Calquence..... | 29, 30 |
| Calquence (acalabrutinib mal) | 29, 30 |
| Caprelsa oral tablet 100 mg, 300 mg | 31 |
| carglumic acid | 32 |
| Cayston | 33 |
| cefoxitin | 9, 10 |
| ceftazidime..... | 9, 10 |
| cefuroxime sodium injection recon soln 750 mg | 9, 10 |
| cefuroxime sodium intravenous recon soln 1.5 gram | 9, 10 |
| Chemet | 34 |
| Chenodal | 35 |
| cinacalcet..... | 192 |
| Cinryze..... | 26 |
| ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 mL | 9, 10 |
| clindamycin in 5 % dextrose..... | 9, 10 |
| clindamycin phosphate injection..... | 9, 10 |
| clindamycin phosphate intravenous..... | 9, 10 |
| Clinimix 5%/D15W Sulfite Free | 273 |
| Clinimix 4.25%/D10W Sulf Free | 273 |
| Clinimix 4.25%/D5W Sulfit Free | 273 |
| Clinimix 5%-D20W(sulfite-free)..... | 273 |
| clobazam oral suspension | 36 |
| clobazam oral tablet | 36 |
| clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg | 80 |
| colistin (colistimethate Na)..... | 9, 10 |

| | |
|---|-----|
| Cometriq oral capsule 100 mg/day(80 mg x1-20 mg x1), 140 mg/day(80 mg x1-20 mg x3), 60 mg/day (20 mg x 3/day) | 37 |
| Copiktra..... | 38 |
| Cotellic..... | 39 |
| Cresemba oral | 40 |
| cromolyn inhalation | 273 |
| cyclobenzaprine oral tablet 10 mg, 5 mg.. | 82 |
| cyclophosphamide oral capsule | 273 |
| cyclophosphamide oral tablet | 273 |
| cyclosporine modified..... | 273 |
| cyclosporine oral capsule..... | 273 |
| Cystagon | 42 |
| Cystaran | 41 |

D

| | |
|---|--------|
| dalfampridine | 43 |
| Daliresp | 44 |
| Daurismo oral tablet 100 mg, 25 mg | 45 |
| deferasirox oral tablet | 46 |
| deferiprone | 47 |
| Diacomit..... | 48 |
| Diazepam Intensol | 80 |
| diazepam oral solution 5 mg/5 mL (1 mg/mL) | 80 |
| diazepam oral tablet | 80 |
| dimethyl fumarate oral capsule,delayed release(DR/EC) 120 mg, 120 mg (14)- 240 mg (46), 240 mg..... | 49 |
| Dotti | 85 |
| Doxy-100 | 9, 10 |
| dronabinol | 273 |
| droxidopa | 145 |
| Dupixent Pen subcutaneous pen injector 200 mg/1.14 mL, 300 mg/2 mL..... | 50, 51 |
| Dupixent Syringe subcutaneous syringe 100 mg/0.67 mL, 200 mg/1.14 mL, 300 mg/2 mL..... | 50, 51 |

E

| | |
|---|--------|
| Emgality Pen..... | 52 |
| Emgality Syringe subcutaneous syringe 120 mg/mL..... | 52 |
| Enbrel Mini | 53, 54 |
| Enbrel subcutaneous solution | 53, 54 |
| Enbrel subcutaneous syringe..... | 53, 54 |
| Enbrel SureClick..... | 53, 54 |
| Engerix-B (PF)..... | 273 |

| | |
|---|--------|
| Engerix-B Pediatric (PF)..... | 273 |
| Epclusa oral pellets in packet 150-37.5 mg, 200-50 mg | 55 |
| Epclusa oral tablet 200-50 mg, 400-100 mg | 55 |
| Epidiolex | 56 |
| Eprontia..... | 228 |
| Erivedge | 59 |
| Erleada | 60 |
| erlotinib oral tablet 100 mg, 150 mg, 25 mg | 61 |
| ertapenem..... | 9, 10 |
| Esbriet oral capsule | 62 |
| estradiol oral..... | 85 |
| estradiol transdermal patch semiweekly ... | 85 |
| estradiol transdermal patch weekly..... | 85 |
| estradiol-norethindrone acet..... | 85 |
| everolimus (antineoplastic) oral tablet 63, 64 | |
| everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg..... | 63, 64 |
| everolimus (immunosuppressive) | 273 |
| Exkivity..... | 65 |

F

| | |
|---|----------|
| fentanyl citrate buccal lozenge on a handle | 231 |
| fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr | 229, 230 |
| fingolimod..... | 70 |
| Fintepla | 66 |
| Firmagon kit w diluent syringe | 273 |
| fluconazole in NaCl (iso-osm) intravenous piggyback 200 mg/100 mL, 400 mg/200 mL..... | 11 |
| formoterol fumarate | 273 |
| Fotivda | 67 |
| Fyavolv | 85 |

G

| | |
|--|-------|
| Gattex 30-Vial..... | 68 |
| Gavreto..... | 69 |
| Gengraf | 273 |
| gentamicin in NaCl (iso-osm) intravenous piggyback 100 mg/100 mL, 60 mg/50 mL, 80 mg/100 mL, 80 mg/50 mL ... | 9, 10 |
| gentamicin injection solution 40 mg/mL ... | 9, 10 |

Gilotrif..... 71
 glatiramer subcutaneous syringe 20 mg/mL,
 40 mg/mL..... 72
 Glatopa subcutaneous syringe 20 mg/mL, 40
 mg/mL..... 72
 granisetron HCl oral..... 273
H
 Harvoni oral pellets in packet 33.75-150 mg,
 45-200 mg 78
 Harvoni oral tablet 90-400 mg..... 78
 Hetlioz..... 79
 Humira Pen 86, 87
 Humira Pen Crohns-UC-HS Start..... 86, 87
 Humira Pen Psor-Uveits-Adol HS 86, 87
 Humira subcutaneous syringe kit 40 mg/0.8
 mL 86, 87
 Humira(CF) Pedi Crohns Starter
 subcutaneous syringe kit 80 mg/0.8 mL,
 80 mg/0.8 mL-40 mg/0.4 mL..... 86, 87
 Humira(CF) Pen Crohns-UC-HS..... 86, 87
 Humira(CF) Pen Pediatric UC 86, 87
 Humira(CF) Pen Psor-Uv-Adol HS 86, 87
 Humira(CF) Pen subcutaneous pen injector
 kit 40 mg/0.4 mL, 80 mg/0.8 mL.... 86, 87
 Humira(CF) subcutaneous syringe kit 10
 mg/0.1 mL, 20 mg/0.2 mL, 40 mg/0.4 mL
 86, 87
 hydromorphone oral tablet extended release
 24 hr 118, 119
 hydroxychloroquine oral tablet 200 mg.... 88
 hydroxyzine HCl oral tablet..... 83
I
 Ibrance..... 89, 90
 ibrutinib..... 91
 Iclusig..... 92
 Idhifa 93
 imatinib oral tablet 100 mg, 400 mg... 94, 95
 Imbruvica oral capsule 140 mg, 70 mg.... 96
 Imbruvica oral suspension 96
 Imbruvica oral tablet 96
 imipenem-cilastatin..... 9, 10
 Inlyta oral tablet 1 mg, 5 mg 99
 Inqovi 100
 Inrebic 101
 Intralipid intravenous emulsion 20 % 273
 ipratropium bromide inhalation 273

ipratropium-albuterol 273
 Iressa 102
 ivermectin oral 103
J
 Jakafi..... 105, 106
 Jinteli..... 85
K
 Kalydeco oral granules in packet 107
 Kalydeco oral tablet 107
 Kerendia..... 108, 109
 Kisqali Femara Co-Pack oral tablet 200
 mg/day(200 mg x 1)-2.5 mg, 400
 mg/day(200 mg x 2)-2.5 mg, 600
 mg/day(200 mg x 3)-2.5 mg 110, 111
 Kisqali oral tablet 200 mg/day (200 mg x 1),
 400 mg/day (200 mg x 2), 600 mg/day
 (200 mg x 3)..... 110, 111
 Korlym 112
 Kynmobi sublingual film 10 mg, 15 mg, 20
 mg, 25 mg, 30 mg 113
L
 lapatinib..... 114, 115
 lenalidomide..... 180, 181
 Lenvima 116
 leuprolide subcutaneous kit..... 74
 levofloxacin in D5W intravenous piggyback
 500 mg/100 mL, 750 mg/150 mL..... 9, 10
 levofloxacin intravenous..... 9, 10
 lidocaine topical adhesive patch,medicated 5
 % 117
 linezolid in dextrose 5%..... 9, 10
 Lonsurf..... 120
 Lorazepam Intensol..... 80
 lorazepam oral tablet 0.5 mg, 1 mg, 2 mg 80
 Lorbrena oral tablet 100 mg, 25 mg..... 121
 Lumakras..... 123
 Lupron Depot..... 74
 Lupron Depot (3 month) 74
 Lupron Depot (4 month) 74
 Lupron Depot (6 Month)..... 74
 Lyllana 85
 Lynparza 124, 125
M
 megestrol oral suspension 400 mg/10 mL
 (40 mg/mL), 625 mg/5 mL (125 mg/mL)
 126

| | |
|---|----------|
| megestrol oral tablet..... | 126 |
| Mekinist oral tablet 0.5 mg, 2 mg ... | 127, 128 |
| Mektovi | 129 |
| memantine oral capsule,sprinkle,ER 24hr | 130 |
| memantine oral solution..... | 130 |
| memantine oral tablet..... | 130 |
| Menest..... | 85 |
| meropenem intravenous recon soln 1 gram, 500 mg | 9, 10 |
| methadone oral solution 10 mg/5 mL, 5 mg/5 mL..... | 118, 119 |
| methadone oral tablet 10 mg, 5 mg. | 118, 119 |
| methotrexate sodium | 273 |
| methotrexate sodium (PF) injection solution | 273 |
| methylprednisolone oral tablet..... | 273 |
| metronidazole in NaCl (iso-os)..... | 9, 10 |
| metyrosine | 165 |
| Mimvey | 85 |
| modafinil oral tablet 100 mg, 200 mg..... | 131 |
| morphine oral tablet extended release.... | 118, 119 |
| moxifloxacin-sod.chloride(iso)..... | 9, 10 |
| Myalept | 132 |
| mycophenolate mofetil..... | 273 |
| mycophenolate sodium | 273 |
| N | |
| nafcillin injection | 9, 10 |
| Namzaric | 130 |
| Natpara | 133 |
| Nayzilam | 134 |
| Nerlynx | 135 |
| nilutamide | 138 |
| Ninlaro | 139 |
| nitisinone | 140 |
| Nivestym | 141, 142 |
| norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg | 85 |
| Nubeqa | 146 |
| Nuedexta | 147 |
| Nuplazid..... | 148 |
| Nurtec ODT | 149 |
| Nyvepria..... | 150, 151 |
| O | |
| Ocaliva | 152 |

| | |
|--|------------|
| octreotide acetate injection solution..... | 153 |
| Odomzo..... | 154 |
| Ofev..... | 155 |
| Omnitrope | 75, 76, 77 |
| ondansetron | 273 |
| ondansetron HCl oral solution | 273 |
| ondansetron HCl oral tablet 4 mg, 8 mg. | 273 |
| Onureg..... | 156 |
| Orenitram | 157 |
| Orgovyx | 158 |
| Orkambi oral granules in packet | 159 |
| Orkambi oral tablet | 159 |
| oxacillin in dextrose(iso-osm)..... | 9, 10 |
| oxacillin injection..... | 9, 10 |
| oxandrolone..... | 8 |
| Oxervate | 160 |
| P | |
| Panretin | 161 |
| Pemazyre..... | 162 |
| penicillamine oral tablet..... | 163 |
| penicillin G potassium injection recon soln 20 million unit..... | 9, 10 |
| penicillin G procaine intramuscular syringe 1.2 million unit/2 mL | 9, 10 |
| penicillin G sodium..... | 9, 10 |
| pentamidine inhalation..... | 273 |
| phenobarbital..... | 84 |
| pimecrolimus..... | 226 |
| Piqray | 167 |
| pirfenidone oral tablet 267 mg, 801 mg.... | 62 |
| Plenaminate..... | 273 |
| Pomalyst..... | 168 |
| posaconazole | 169 |
| Prehevbrio (PF)..... | 273 |
| Premasol 10 % | 273 |
| Privigen | 104 |
| Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL | 57, 58 |
| Prograf oral granules in packet | 273 |
| Prolastin-C intravenous recon soln | 6 |
| Prolia | 170, 171 |
| Promacta | 172, 173 |
| promethazine oral..... | 83 |
| Pulmozyme | 273 |

pyrimethamine 174

Q

Qinlock..... 175

R

Recombivax HB (PF)..... 273

Repatha 176, 177

Repatha Pushtronex 176, 177

Repatha SureClick 176, 177

Retevmo oral capsule 40 mg, 80 mg..... 178

Revcovi 179

Revlimid..... 180, 181

riluzole 182

Rinvoq oral tablet extended release 24 hr 15

mg, 30 mg, 45 mg 183, 184

roflumilast..... 44

Rozlytrek oral capsule 100 mg, 200 mg . 185

Rubraca 186, 187

rufinamide 188

Rydapt 189

S

Sajazir 91

Sandimmune oral solution 273

sapropterin..... 190

Scemblix oral tablet 20 mg, 40 mg 191

Signifor 193

sildenafil (Pulmonary Arterial

Hypertension) oral tablet..... 166

sirolimus..... 273

Sirturo 194

Skyrizi subcutaneous pen injector .. 195, 196

Skyrizi subcutaneous syringe 150 mg/mL

..... 195, 196

Skyrizi subcutaneous wearable injector 180

mg/1.2 mL (150 mg/mL), 360 mg/2.4 mL

(150 mg/mL) 195, 196

sodium phenylbutyrate..... 164

Somavert 197

sorafenib..... 136, 137

Sprycel oral tablet 100 mg, 140 mg, 20 mg,

50 mg, 70 mg, 80 mg 198

Stelara subcutaneous solution 199, 200

Stelara subcutaneous syringe 45 mg/0.5 mL,

90 mg/mL..... 199, 200

Stivarga 201

streptomycin..... 9, 10

Sucraid 202

sunitinib..... 203

Symdeko 204

Sympazan..... 36

Synarel 205

Synribo..... 273

T

Tabrecta..... 206

tacrolimus oral 273

tacrolimus topical..... 226

Tafinlar..... 208, 209

Tagrisso..... 210

Taltz Autoinjector 211

Taltz Syringe..... 211

Talzenna oral capsule 0.25 mg, 0.5 mg, 0.75

mg, 1 mg 212

Tasigna oral capsule 150 mg, 200 mg, 50

mg 214

tazarotene topical cream 215

tazarotene topical gel 215

Tazicef injection..... 9, 10

Tazverik 216

Teflaro..... 9, 10

Tepmetko 217

teriparatide 218, 219

testosterone cypionate..... 97, 98

testosterone enanthate 97, 98

testosterone transdermal gel in metered-dose

pump 10 mg/0.5 gram /actuation, 20.25

mg/1.25 gram (1.62 %) 143, 144

testosterone transdermal gel in packet 1 %

(25 mg/2.5gram), 1 % (50 mg/5 gram),

1.62 % (20.25 mg/1.25 gram), 1.62 %

(40.5 mg/2.5 gram) 143, 144

testosterone transdermal solution in metered

pump w/app..... 143, 144

tetrabenazine oral tablet 12.5 mg, 25 mg 220

Thalomid oral capsule 100 mg, 150 mg, 200

mg, 50 mg 221, 222

Tibsovo 223

tigecycline 9, 10

tobramycin in 0.225 % NaCl 224

tobramycin inhalation 224

tobramycin sulfate injection solution.... 9, 10

tolvaptan..... 225

topiramate oral capsule, sprinkle 228

topiramate oral tablet 228

| | |
|---|----------|
| Travasol 10 % | 273 |
| Trelstar intramuscular suspension for reconstitution..... | 273 |
| tretinoin topical | 227 |
| trientine | 232, 233 |
| Trikafta..... | 234 |
| TrophAmine 10 %..... | 273 |
| Trulicity..... | 73 |
| Truseltiq oral capsule 100 mg/day (100 mg x 1), 125 mg/day(100 mg x1-25mg x1), 50 mg/day (25 mg x 2), 75 mg/day (25 mg x 3) | 235 |
| Tukysa oral tablet 150 mg, 50 mg | 236 |
| Turalio oral capsule 200 mg | 237 |
| V | |
| Valchlor..... | 238 |
| Valtoco..... | 239 |
| vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg..... | 9, 10 |
| vancomycin oral capsule 125 mg, 250 mg | 240 |
| Venclexta oral tablet 10 mg, 100 mg, 50 mg | 241, 242 |
| Venclexta Starting Pack..... | 241, 242 |
| Verzenio..... | 243, 244 |
| Vitrakvi oral capsule 100 mg, 25 mg..... | 245 |
| Vitrakvi oral solution | 245 |
| Vizimpro | 246 |
| Vonjo..... | 247 |
| voriconazole..... | 11, 248 |
| Vosevi | 249 |
| Votrient | 250, 251 |
| Vyndamax | 207 |

| | |
|---|----------|
| W | |
| Welireg..... | 252 |
| X | |
| Xalkori | 253, 254 |
| Xatmep..... | 273 |
| Xeljanz oral solution | 255, 256 |
| Xeljanz oral tablet..... | 255, 256 |
| Xeljanz XR..... | 255, 256 |
| Xgeva | 273 |
| Xolair subcutaneous recon soln | 257, 258 |
| Xolair subcutaneous syringe 150 mg/mL, 75 mg/0.5 mL..... | 257, 258 |
| Xospata | 259 |
| Xpovio oral tablet 100 mg/week (50 mg x 2), 40 mg/week (40 mg x 1), 40mg twice week (40 mg x 2), 60 mg/week (60 mg x 1), 60mg twice week (120 mg/week), 80 mg/week (40 mg x 2), 80mg twice week (160 mg/week) | 260, 261 |
| Xtandi oral capsule | 262 |
| Xtandi oral tablet 40 mg, 80 mg | 262 |
| Xyrem | 263 |
| Y | |
| Yonsa | 264 |
| Z | |
| Zejula | 265 |
| Zelboraf..... | 266, 267 |
| Zolinza | 268 |
| Zonisade..... | 228 |
| zonisamide | 228 |
| Zydelig | 269 |
| Zykadia | 270 |